- 1 Genome-wide meta-analysis identifies novel maternal risk variants and enables 2 polygenic prediction of preeclampsia and gestational hypertension 3 Michael C. Honigberg^{1-3*}, Buu Truong^{2,3*}, Raiyan R. Khan⁴, Brenda Xiao⁵, Laxmi Bhatta^{6,7}, Thi Ha Vy⁸, Rafael F. Guerrero⁹, Art Schuermans^{2,3,10}, Margaret Sunitha Selvaraj^{2,3}, Aniruddh P. Patel¹⁻³, Satoshi Koyama^{2,3}, So Mi Jemma Cho^{2,3,11}, Shamsudheen Karuthedath Vellarikkal^{3,12}, Mark Trinder^{3,13}, Sarah M. Urbut¹⁻³, Kathryn J. Gray^{14,15}, Ben M. Brumpton^{6,7}, Snehal Patil¹⁶, 4 5 6 7 Sebastian Zöllner¹⁶, Mariah C. Antopia¹⁷, Genes & Health Research Team, Estonian Biobank 8 Research Team, nuMoM2b Research Team, Richa Saxena^{3,15}, Girish N. Nadkarni⁸, Ron Do⁸, Qi 9 Yan¹⁸, Itsik Pe'er⁴, Shefali Setia Verma⁵, Rajat M. Gupta^{3,12}, David M. Haas¹⁹, Hilary C. Martin²⁰, 10 David A. van Heel²¹, Triin Laisk²², Pradeep Natarajan^{1-3,15} 11 12 13 ¹Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, MA, 14 USA ²Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, 15 Boston, MA, USA 16 17 ³Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA 18 ⁴Department of Computer Science, Columbia University, New York, NY, USA 19 20 ⁵University of Pennsylvania, Philadelphia, PA, USA ⁶K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, 21 22 NTNU, Norwegian University of Science and Technology, Trondheim, Norway 23 ⁷HUNT Research Centre, Department of Public Health and Nursing, NTNU, Norwegian 24 University of Science and Technology, Levanger, Norway ⁸The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount 25 26 Sinai, New York, NY, USA ⁹Department of Biological Sciences, North Carolina State University, Raleigh, NC, USA 27 ¹⁰Faculty of Medicine, KU Leuven, Leuven, Belgium 28 ¹¹Integrative Research Center for Cerebrovascular and Cardiovascular Diseases, Seoul, 29 30 Republic of Korea 31 ¹²Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, 32 MA, USA 33 ¹³Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada 34 ¹⁴Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, MA, USA ¹⁵Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA 35 36 ¹⁶Department of Biostatistics and Center for Statistical Genetics, University of Michigan School 37 of Public Health, Ann Arbor, MI, USA ¹⁷Department of Integrative Biology, University of Texas at San Antonio, San Antonio, TX, USA 38 39 ¹⁸Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA 40 ¹⁹Indiana University School of Medicine, Indianapolis, IN, USA ²⁰Department of Human Genetics, Wellcome Sanger Institute, Cambridge, UK 41 ²¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary 42 43 University of London, London, UK ²²Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia 44 45 46 *These authors contributed equally. 47
- 48

49 **Corresponding Authors:**

- 50 51 Michael C. Honigberg, N
- 51 Michael C. Honigberg, MD MPP
 52 Massachusetts General Hospital
- 53 185 Cambridge Street, CPZN 3.187
- 53 Tob Gambridge Street, CPZN 3.16
- 54 Boston, MA 02114 55 Phone: 617-726-1843
- 56 Fax: 617-726-2203
- 57 Email: mhonigberg@mgh.harvard.edu
- 58 Twitter: @mchonig
- 5960 Pradeep Natarajan, MD MMSc
- 61 Massachusetts General Hospital
- 62 185 Cambridge Street, CPZN 3.184
- 63 Boston, MA 02114
- 64 Phone: 617-726-1843
- 65 Fax: 617-726-2203
- 66 Email: pnatarajan@mgh.harvard.edu
- 67 Twitter: @pnatarajanmd

68 Abstract

69	Preeclampsia and gestational hypertension are common pregnancy complications
70	associated with adverse maternal and offspring outcomes. Current tools for prediction,
71	prevention, and treatment are limited. We tested the association of maternal DNA sequence
72	variants with preeclampsia in 20,064 cases and 703,117 controls and with gestational
73	hypertension in 11,027 cases and 412,788 controls across discovery and follow-up cohorts
74	using multi-ancestry meta-analysis. Altogether, we identified 18 independent loci associated
75	with preeclampsia/eclampsia and/or gestational hypertension, 12 of which are novel (e.g.,
76	MTHFR-CLCN6, WNT3A, NPR3, PGR, and RGL3), including two loci (PLCE1, FURIN)
77	identified in multi-trait analysis. Identified loci highlight the role of natriuretic peptide signaling,
78	angiogenesis, renal glomerular function, trophoblast development, and immune dysregulation.
79	We derived genome-wide polygenic risk scores that predicted preeclampsia/eclampsia and
80	gestational hypertension in external datasets, independent of first trimester risk markers.
81	Collectively, these findings provide mechanistic insights into the hypertensive disorders of
82	pregnancy and advance pregnancy risk stratification.

83 The hypertensive disorders of pregnancy (HDPs) represent a leading global cause of 84 maternal and neonatal morbidity and mortality and account for approximately 14% of maternal deaths worldwide^{1,2}. Up to 15% of child-bearing women experience an HDP in at least one 85 86 pregnancy^{3,4}. The HDPs include preeclampsia, defined as new-onset hypertension or worsening 87 hypertension after 20 weeks' gestation plus proteinuria or other evidence of end-organ 88 dysfunction; gestational hypertension, defined as new-onset hypertension without 89 accompanying features of preeclampsia; and eclampsia, defined as progression of preeclampsia to maternal seizures^{5,6}. In addition to short-term risks of end-organ failure and 90 91 death in the absence of prompt recognition and treatment, those who develop HDPs have 92 roughly two-fold long-term risk of cardiovascular disease events and premature cardiovascular 93 mortality compared with those who experience only normotensive pregnancies for reasons that 94 remain incompletely understood^{7,8}. 95 The pathophysiology of the HDPs is increasingly recognized to be heterogeneous with 96 both maternal and fetal contributions. In the contemporary model of preeclampsia 97 pathophysiology, defective trophoblast invasion in early placental development and incomplete remodeling of the maternal spiral arteries lead to placental ischemia later in gestation^{1,9,10}. The 98 99 distressed placenta secretes an excess of circulating anti-angiogenic proteins (e.g., soluble fms-100 like tyrosine kinase receptor 1 [sFlt-1] and soluble endoglin) which induce the systemic maternal 101 endothelial dysfunction and vasoconstriction that drive the clinical manifestations of 102 preeclampsia (hypertension and proteinuria)¹¹. In addition, maternal cardiometabolic risk factors (e.g., pre-pregnancy chronic hypertension, diabetes, obesity) and pre-pregnancy kidney and 103

autoimmune disease strongly predict preeclampsia^{1,12} and influence early placentation as well
as maternal vascular adaptation to pregnancy^{10,13}.

Genetic analysis may yield novel mechanistic insights into the pathophysiology of the
 HDPs and may also help improve pregnancy risk prediction. An estimated 31-35% of
 preeclampsia predisposition has been attributed to maternal genetics using familial aggregation-

109	based approaches ^{14,15} . However, few genetic loci linked to preeclampsia have been identified
110	and robustly validated to date. Several fetal variants near the FLT1 gene, which encodes
111	placenta-derived sFlt-1, have been reported to associate with preeclampsia ^{16,17} . Steinthorsdottir
112	et al. recently performed the largest maternal GWAS of preeclampsia to date and identified
113	associations near FTO (the first reported obesity-associated locus) ¹⁸ , ZNF831, and several
114	other blood pressure-associated genes (MECOM, FGF5, and SH2B3) in combined meta-
115	analysis of 12,150 cases and 164,098 controls ¹⁷ . In addition, several studies have now reported
116	that increased maternal polygenic risk of hypertension associates with risk of HDPs ^{17,19-22} .
117	In this work, we performed expanded multi-ancestry GWAS meta-analysis for
118	preeclampsia/eclampsia and separately performed GWAS for gestational hypertension. We
119	then used these results to train and test polygenic risk scores (PRS) for each outcome in
120	independent datasets (Extended Data Fig. 1).
121	
122	Results
123	Association of common genetic variants with preeclampsia/eclampsia and gestational
124	hypertension.
125	We tested the association of common variants (minor allele frequency [MAF] \ge 1%) with
126	preeclampsia/eclampsia among 17,150 cases and 451,241 controls in discovery analysis

127 (78.0% European, 21.2% Asian, 0.5% admixed American, and 0.3% African ancestry;

128 **Supplementary Table 1**) using multi-ancestry fixed-effects meta-analysis in METAL²³. Cases

129 were identified principally using International Classification of Diseases (ICD) codes and

130 phecodes corresponding to preeclampsia and, where available, eclampsia (**Supplementary**

Tables 1-3); controls were generally either women with exclusively normotensive pregnancies

132 or all women without codes corresponding to hypertension in pregnancy¹⁷. In discovery

analysis, we identified 12 independent loci at the commonly used statistical significance

threshold of $P < 5 \times 10^{-8}$, including 6 previously nominated by Steinthorsdottir et al. in maternal or

135 fetal GWAS (MECOM [3q26], FGF5 [4q21], SH2B3 [12q22], FLT1 [13q12], FTO [16q12], and ZNF831 [20q13])¹⁷ and 6 additional loci (MTHFR-CLCN6 [1p36], WNT3A [1q42], MICA [6p21], 136 137 LINC00484 [9q22], PGR [11q22], and RGL3 [19p13]; Table 1, Supplementary Fig. 2a, 138 Supplementary Table 4). 139 We pursued replication of these GWAS results in 4 follow-up cohorts that collectively 140 included 2,914 preeclampsia/eclampsia cases and 251,876 controls (96.7% European, 3.1% 141 African, and 0.3% admixed American ancestry). We replicated 7 of 12 associations from 142 discovery analysis with P<0.05 and consistent direction of effect, including the novel 143 associations at MTHFR-CLCN6, PGR, and RGL3 (Table 1). Ten associations had consistent 144 direction of effect in follow-up cohorts, and 11 of 12 associated loci retained genome-wide 145 significance in combined meta-analysis of preeclampsia/eclampsia discovery and follow-up 146 cohorts. In meta-analysis of discovery and follow-up cohorts, 2 additional loci attained genome-147 wide significance (FGL1 [8p22] and UPB1 [22g11]), vielding a total of 13 loci associated with 148 preeclampsia/eclampsia with genome-wide significance in combined meta-analysis (Fig. 1a). 149 We did not observe inflation in test statistics (lambda genomic inflation factor: 1.038, 150 Supplementary Fig. 1a). There was no discernible heterogeneity of these associations across ancestries (**Supplementary Table 5**). Conditional analysis in GCTA-COJO²⁴ identified a second 151 152 independent association on chromosome 20 near ZBTB46 (lead variant rs4809370, OR 1.08, 153 $P=1.4 \times 10^{-8}$).

We next tested the association of common variants with gestational hypertension among 8,961 cases and 184,925 controls in discovery analysis (91.3% European, 6.7% Asian, 0.7% African, 1.3% admixed American) and among 2,066 cases and 227,863 controls in follow-up cohorts (96.3% European, 3.4% African, 0.3% admixed American, **Supplementary Tables 1-2**). Gestational hypertension cases were identified primarily based on qualifying ICD codes for gestational hypertension and an absence of qualifying codes for preeclampsia/eclampsia. In discovery analysis, we identified 7 independent genome-wide significant loci associated with

161	gestational hypertension, including 4 also associated with preeclampsia/eclampsia (MECOM,
162	FGF5, RGL3, and ZNF831) and 3 additional associations (NPR3 [5p13], TNS2-CSAD [12q13],
163	and PREX1 [20q13]; Table 2). Four of 7 significant associations replicated with P<0.05 in
164	follow-up cohorts (FGF5, RGL3, PREX1, and ZNF831), and all 7 loci had consistent direction of
165	effect in follow-up cohorts. In combined meta-analysis of discovery and follow-up cohorts, 6 of 7
166	loci retained genome-wide significance, and the MTHFR-CLCN6 locus (1p36) additionally
167	reached genome-wide significance, yielding a total of 7 loci associated with gestational
168	hypertension in combined meta-analysis (Fig. 1b). As with preeclampsia/eclampsia, we did not
169	observe inflation in test statistics (lambda genomic inflation factor: 0.976, Supplementary Fig.
170	1b). Stratified analyses suggested potential heterogeneity of association by ancestry
171	(P _{heterogeneity} =0.001) at the MECOM locus, with an inverse association with the lead risk variant
172	observed in those with admixed American ancestry (Supplementary Table 5).
173	
174	Genetic correlation across hypertension-related phenotypes.
175	We used cross-trait LD score regression ²⁵ to assess genetic correlations among
176	preeclampsia/eclampsia, gestational hypertension, systolic blood pressure (SBP), and diastolic
177	blood pressure (DBP) ²⁶ . Preeclampsia/eclampsia and gestational hypertension were strongly
178	genetically correlated ($r_g = 0.71$, SE = 0.08). SBP demonstrated stronger genetic correlation with
179	gestational hypertension (r_g = 0.73, SE = 0.06) vs. preeclampsia/eclampsia (r_g = 0.52, SE =
180	0.05). Of note, correlation of SBP with gestational hypertension ($r_g = 0.73$) was larger than that
181	of SBP with DBP ($r_g = 0.62$, SE = 0.03, in the Million Veteran Program ²⁶ , with similar genetic

- 182 correlation between SBP and DBP observed previously in the UK Biobank²⁷). Genetic
- 183 correlations with the HDPs were stronger for SBP vs. DBP (**Supplementary Table 6**).
- 184
- 185

186 Multi-trait analysis of GWAS

187 Given the high degree of genetic correlation observed between preeclampsia/eclampsia 188 and gestational hypertension noted earlier, we used multi-trait analysis of genome-wide 189 association summary statistics (MTAG)²⁸ to boost power to identify additional associated 190 variants. Consistent with this high degree of correlation, MTAG yielded very similar results for 191 each trait (displayed for preeclampsia/eclampsia in Extended Data Fig. 2). MTAG identified 2 192 additional loci with genome-wide significance (Supplementary Table 7): PLCE1 (10q23), a 193 blood pressure-associated gene involved in glomerular podocyte development²⁹, which also 194 narrowly missed statistical significance in combined meta-analysis of gestational hypertension discovery and follow-up cohorts ($P=6.0 \times 10^{-8}$); and FURIN (15q26), whose product is a protein 195 convertase involved in processing pro-natriuretic peptides³⁰ and whose expression is decreased 196 197 in preeclamptic placentas³¹.

198

199 Gene prioritization at preeclampsia/eclampsia and gestational hypertension risk loci.

200 To prioritize causal genes, we first performed colocalization analysis with expression 201 guantitative trait loci (eQTLs) within ±500 kilobases of lead variants across 52 tissues in the Genotype-Tissue Expression project (GTEx) (Supplementary Tables 8-9)³². Colocalization 202 203 analyses implicated FGF5 and NPR3 as causal genes at their respective loci. The lead variant 204 at the MTHFR-CLCN6 locus colocalized with CLCN6 eQTLs as well as expression of NPPA 205 (which encodes the precursor to atrial natriuretic peptide [ANP]). The lead 206 preeclampsia/eclampsia variant at the ZNF831 locus colocalized with multiple genes but most 207 strongly with ZBTB46 expression, including in arterial tissue. We also observed multiple 208 colocalizations with WNT3A (WNT3A, GJC2, and mitochondrial proteins IBA57 and MPRL55), 209 MICA (CLIC1 and psoriasis-associated genes TCF19, CCHCR1, and PSORS1C1), and RGL3 210 (ZNF627 and EPOR). We observed no strong colocalizations with lead variants at LINC00484, 211 PGR, SH2B3, FLT1, FTO, or TNS2-CSAD.

Next, we queried variant-to-gene evidence in Open Targets Genetics v7
(Supplementary Tables 10-11)³³ and generated polygenic priority scores (PoPS,
Supplementary Table 12)³⁴ for lead variants. Both approaches nominated *MECOM*, *FGF5*, *SH2B3*, *FTO*, and *NPR3* as the most likely causal gene and their respective loci. PoPS
prioritized *NPPA* as the most likely causal gene at the *MTHFR-CLCN6* locus and *TRPC6* as the
most likely causal gene at the *PGR* locus.

218 To further understand how identified genes might influence HDP risk, we queried lead maternal variants in the fetal GWAS for maternal preeclampsia from Steinthorsdottir et al.¹⁷ 219 (Supplementary Table 13). As published previously^{16,17}, the lead *FLT1* variant was strongly 220 associated with preeclampsia ($P=3.9\times10^{-11}$); all other lead variants had $P>10^{-4}$ in the fetal 221 222 GWAS. In addition, we queried nearest genes and those prioritized by colocalization, variant-to-223 gene scores, and/or PoPS in a publicly available database of the human placental transcriptome including preeclampsia cases and controls (**Supplementary Table 14**)³⁵. Consistent with the 224 correlation of increased circulating placental sFlt-1 with preeclampsia incidence^{11,36}, *FLT1* gene 225 226 expression was increased in preeclamptic placentas (log₂(fold change) 0.39, false discovery 227 rate-adjusted P=0.003). Expression of WNT3A, which occurs almost exclusively in the placenta³⁷, was increased in preeclamptic placentas vs. healthy controls (log₂(fold change) 0.21, 228 adjusted P=0.029), in line with another recent study³⁸. OBSCN, which was most strongly 229 230 prioritized by PoPS at the WNT3A locus, was also overexpressed in preeclamptic vs. control 231 placentas (log_2 (fold change) 0.18, adjusted P=0.037). Furthermore, preeclamptic placentas 232 demonstrated lower expression of ARHGAP42—which sits adjacent to PGR and encodes Rho 233 GTP-ase activating protein 42, a known regulator of vascular tone and blood pressure expressed selectively in smooth muscle cells³⁹—compared with controls (log₂(fold change) 234 235 -0.18, adjusted *P*=0.004).

We analyzed expression of prioritized genes in a dataset of single-nuclei RNA
 sequencing (snRNA-seq) from non-atherosclerotic human aortic tissue. SnRNA-seq identified

238 subpopulations of vascular smooth muscle cells, fibromyocytes, fibroblasts, endothelial cells, 239 macrophages, natural killer T cells, and neuronal cells. The greatest enrichment was seen in the 240 two endothelial cell (EC) populations and in macrophages (Extended Data Fig. 3). The EC1 241 subpopulation is enriched for genes in angiogenesis and lipoprotein assembly and clearance, 242 while the EC2 subpopulation is enriched for genes in extracellular matrix production and integrin expression⁴⁰. Relative expression in ECs vs. other cell types was strongest for *FLT1* (EC1/EC2), 243 244 ZBTB46 (EC1), and MECOM (EC2). 245 246 Training and testing polygenic risk scores for preeclampsia/eclampsia and gestational 247 hypertension. We used PRS-CS⁴¹ to construct genome-wide PRS for preeclampsia/eclampsia 248 249 (PRS_{preeclampsia}) and gestational hypertension (PRS_{GH}) from our corresponding discovery GWAS 250 summary statistics. In addition, since blood pressure polygenic risk has previously been 251 associated with HDPs^{17,19,20}, we used PRS-CS to derive a PRS for SBP (PRS_{SBP}) using the SBP GWAS from the Million Veteran Program²⁶ to compare prediction across scores and determine 252 253 whether a linear combination of each HDP PRS and PRS_{SBP} improves performance. 254 We tuned polygenic scores among 423 women with a history of 255 preeclampsia/eclampsia, 482 women with a history of gestational hypertension only, and 256 211,129 parous women without a reported history of HDPs in the UK Biobank. The global shrinkage parameter of 1x10⁻⁴ was chosen for PRS_{preeclampsia} and PRS_{SBP} and of 1x10⁻⁶ for 257 PRS_{GH} as these values generated the highest R^2 (Supplementary Table 15). A linear 258 259 combination of PRS_{preeclampsia} and PRS_{SBP} (PRS_{preeclampsia+SBP}) improved performance vs. each 260 score individually for the outcome of preeclampsia (Supplementary Table 16). 261 The individual and combination PRS tuned in the UK Biobank were carried forward for 262 external validation in two complementary datasets: a Norwegian population-based cohort linked 263 to the Medical Birth Register of Norway (HUNT, preeclampsia/eclampsia only) and a

prospective U.S. pregnancy cohort (nuMoM2b). Among 25,582 Norwegian women in HUNT (1,569 [6.1%] with preeclampsia/eclampsia), the prevalence of preeclampsia/eclampsia ranged from ~4% among women in the bottom decile of $PRS_{preeclampsia+SBP}$ to ~10% among the top decile of $PRS_{preeclampsia+SBP}$ (**Fig. 2a**). After adjustment for age at birth, age², and the first 10 principal components (PC) of ancestry, the OR corresponding to the top 10%vs. bottom 90% of $PRS_{preeclampsia+SBP}$ was 1.85 (95% CI 1.61-2.13, *P*=6.3x10⁻¹⁸). $PRS_{preeclampsia+SBP}$ increased Nagelkerke's *R*² by 28.5% compared with the $PRS_{preeclampsia}$ alone and by 79.3% compared with

271 PRS_{SBP} alone (**Supplementary Table 17**).

272 We next tested PRS performance in the prospective, multi-ancestry nuMoM2b cohort of 273 U.S. women recruited in the first trimester of their first pregnancy, including 481 (6.4%) who 274 developed preeclampsia, 1,319 (17.5%) who developed gestational hypertension, and 5,744 275 with normotensive pregnancies (overall 73.6% European, 16.5% African, and 1.0% admixed 276 American ancestry). Rates of preeclampsia/eclampsia ranged from ~4% among women in the 277 bottom decile of PRS_{preeclampsia+SBP} to ~10% among the top decile of PRS_{preeclampsia+SBP} (Fig. 2b). 278 Rates of gestational hypertension ranged from ~9% among women in the bottom decile of 279 PRS_{GH+SBP} to ~24% among the top decile of PRS_{GH+SBP} (**Fig. 2c**). As in HUNT, incorporating 280 SBP PRS in linear combination boosted PRS performance for HDPs, especially for gestational 281 hypertension, although PRS performance was better for European ancestry vs. other women 282 (Supplementary Table 18). After adjustment for age, PC 1-10, and self-reported race/ethnicity, 283 PRS_{preeclampsia+SBP} and PRS_{GH+SBP} each predicted their respective outcomes (preeclampsia/eclampsia: OR 1.78, 95% CI 1.35-2.31, for top 10% vs. bottom 90% 284 PRS_{preeclampsia+SBP}, P=2.6x10⁻⁵; gestational hypertension: OR 1.52, 95% CI 1.26-1.84, for top 10% 285 286 vs. bottom 90% PRS_{GH+SBP}, $P=1.0\times10^{-5}$). As pre-pregnancy hypertension and obesity are 287 established clinical predictors of HDPs, we performed further adjustment for first trimester SBP, 288 antihypertensive medication use (as a marker of chronic hypertension), and body mass index 289 (BMI). After this additional adjustment, the scores both remained predictive

290 (preeclampsia/eclampsia: OR 1.64, 95% CI 1.23-2.15, for top 10% vs. bottom 90%

PRS_{preeclampsia+SBP}, $P=5.1\times10^{-4}$; gestational hypertension: OR 1.53, 95% Cl 1.26-1.85, for top 10% vs. bottom 90% PRS_{GH+SBP}, $P=1.0\times10^{-5}$). Compared with a model including age, PC 1-10, selfreported race/ethnicity, first trimester SBP, antihypertensive medication use, and first trimester BMI, addition of PRS_{preeclampsia+SBP} improved the C-statistic for preeclampsia/eclampsia from 0.690 to 0.701 (+0.011, 95% Cl 0.001-0.021, Delong's $P=3.7\times10^{-2}$). Similarly, addition of PRS_{GH+SBP} improved the C-statistic for gestational hypertension from 0.649 to 0.659 (+0.010, 95% Cl 0.003-0.018, Delong's $P=5.7\times10^{-3}$).

298 Low-dose aspirin starting after 12 weeks' gestation represents an evidence-based but underutilized⁴² strategy to reduce risk of preeclampsia. To further probe the potential clinical 299 300 impact of incorporating PRS to guide aspirin allocation, we examined aspirin eligibility according to current U.S. Preventive Service Task Force major criteria⁴³ with and without addition of 301 302 PRS_{preeclampsia+SBP} as an additional eligibility criterion in the nuMoM2b cohort. Among singleton, 303 nulliparous women (i.e., the population enrolled in nuMoM2b), major criteria for aspirin eligibility 304 are chronic pre-pregnancy hypertension, pre-gestational diabetes, kidney disease, and autoimmune disease.⁴³ Major risk factors identified only a small proportion of the cohort that 305 306 developed HDPs (Table 3), and aspirin would have been recommended in only 17.5% of 307 women who developed preeclampsia/eclampsia (i.e., sensitivity of major risk factors alone was 308 17.5%), with a positive predictive value of 12.8%. Incorporating the top 10% of PRS_{preeclampsia+SBP} 309 increased identification of the aspirin-eligible proportion to 30.4% of women with 310 preeclampsia/eclampsia (i.e., sensitivity 30.4% [95% CI 26.2-34.5%]) with specificity of 83.3% 311 (95% CI 82.5-84.2%), positive predictive value of 11.0% (95% CI 9.3-12.7%), and negative 312 predictive value of 94.6% (95% CI 94.1-95.2%; Table 3). Expanding aspirin eligibility further to 313 include the top 25% of PRS_{preeclampsia+SBP} captured nearly half (47.0%) of women who developed 314 preeclampsia/eclampsia. Addition of high PRSpreeclampsia+SBP to major risk factors to up-classify 315 risk of preeclampsia/eclampsia vs. other pregnancies yielded net reclassification of +1.8% (95%

316 CI -0.3 to +4.0%) for top 5% PRS_{preeclampsia+SBP}, +4.3% (95% CI 1.3-7.3%) for top 10%

 $\label{eq:preclampsia+SBP} 317 \qquad \mathsf{PRS}_{\mathsf{preeclampsia+SBP}}, \text{ and } +8.3\% \ (95\% \ \mathsf{CI} \ 3.9\text{-}12.6\%) \ \text{for top } 25\% \ \mathsf{PRS}_{\mathsf{preeclampsia+SBP}} \ \textbf{(Table 3)}.$

318

319 Phenome-wide associations with preeclampsia/eclampsia and gestational hypertension

320 polygenic risk.

321 We performed sex-stratified phenome-wide association analysis (pheWAS) for 322 PRS_{preeclampsia} and PRS_{GH} across 1,445 phecode-based phenotypes in the UK Biobank. 323 PRS_{preeclampsia} was significantly associated with 36 phenotypes in women and 37 phenotypes in men with Bonferroni-corrected statistical significance ($P < 0.05/1,445 = 3.5 \times 10^{-5}$); PRS_{GH} was 324 325 significantly associated with 25 and 32 phenotypes in women and men, respectively (Fig. 3). 326 PRS_{preeclampsia} and PRS_{GH} were most strongly associated with hypertension in both sexes 327 (PRS_{preeclamosia}: OR_{women} 1.15 per SD, 95% CI 1.14-1.16, *P*=1.4x10⁻¹⁷⁵; OR_{men} 1.12 per SD, 95% CI 1.11-1.13, P=7.5x10⁻¹¹²; PRS_{GH}: OR_{women} 1.15 per SD, 95% CI 1.14-1.16, P=5.1x10⁻¹⁸⁴; OR_{men} 328 1.13 per SD, 95% CI 1.11-1.14, P=1.3x10⁻¹³³). Other strong phenotypic associations included 329 330 hypercholesterolemia, type 2 diabetes, obesity, and atherosclerotic cardiovascular disease 331 (Supplementary Tables 19-20). PRSpreeclampsia predicted ischemic heart disease in women (OR 1.09 per SD, 95% CI 1.07-1.11, P=4.4x10⁻²⁷) and men (OR 1.09 per SD, 95% CI 1.07-1.10, 332 $P=2.6 \times 10^{-40}$), as did PRS_{GH} (OR_{women} 1.07 per SD, 95% CI 1.05-1.08, $P=4.4 \times 10^{-16}$; OR_{men} 1.08 333 per SD, 95% CI 1.07-1.09, P=1.4x10⁻³⁵). These similar associations between sexes suggest that 334 335 most genes identified are not pregnancy-specific, but rather that pregnancy likely unmasks underlying risk. PRSpreeclampsia was also associated with several autoimmune phenotypes, 336 337 including celiac disease, type 1 diabetes, hypothyroidism (in women), and a suggestive 338 association with rheumatoid arthritis in women ($P=5.7 \times 10^{-6}$), whereas type 1 diabetes and celiac 339 disease were not significantly associated with PRS_{GH} in either sex.

- 340
- 341

342 Discussion

343 We present an expanded multi-ancestry maternal genome-wide association analysis of 344 preeclampsia/eclampsia and, to our knowledge, the first distinct GWAS of gestational 345 hypertension, two pregnancy complications on the spectrum of HDPs with substantial 346 associated public health impact. Altogether, we identified 18 independent genomic loci 347 associated with preeclampsia/eclampsia and/or gestational hypertension: 13 loci associated 348 with preeclampsia/eclampsia; 7 loci associated with gestational hypertension, of which 4 overlap 349 with preeclampsia/eclampsia: and 2 additional loci associated with both phenotypes in multi-trait 350 analysis. Identified loci highlight the role of angiogenesis and endothelial cell function (FLT1, 351 ZBTB46), natriuretic peptide signaling (NPPA, NPR3, FURIN), renal glomerular function 352 (TRPC6, TNS2, PLCE1), and immune dysregulation (MICA, SH2B3) in the pathogenesis of these conditions, with some loci (*FLT1*^{16,17,36}, *WNT3A*^{38,44}) previously described to influence risk 353 354 via the fetal genome. Furthermore, we demonstrated that an HDP PRS augmented by a systolic 355 blood pressure PRS stratified risk of HDP. Polygenic risk scores predicted HDP risk among 356 nulliparous women independent of first trimester blood pressure and BMI, indicating potential 357 clinical utility of these scores risk for pregnancy risk stratification. Collectively, these findings 358 may have implications for advancing HDP prediction, prevention, and treatment.

359 First, our findings provide insights into mechanisms of HDP pathogenesis and underscore the causal role of blood pressure. As in previous GWAS of preeclampsia¹⁷, most 360 361 genetic associations we identified were also associated with blood pressure²⁹, and genetic 362 correlation between blood pressure and the HDPs, especially gestational hypertension, was 363 high. These findings align with prior work demonstrating heightened polygenic BP risk in those 364 with HDPs^{17,19,20}. Indeed, we observed that integrating SBP PRS with HDP PRS in linear 365 combination further improved predictive performance for both preeclampsia/eclampsia and 366 gestational hypertension. The recently published randomized CHAP trial of treatment for mild 367 chronic hypertension in pregnancy demonstrated that lowering blood pressure

pharmacologically reduced risk of progression to preeclampsia⁴⁵, supporting the notion that
elevated blood pressure is not merely a clinical manifestation of the HDPs but also plays a
causal role in disease pathogenesis.

371 Second, our GWAS findings suggest a key role of natriuretic peptide signaling in the 372 pathogenesis of the HDPs. The natriuretic peptides (e.g., ANP, B-type natriuretic peptide [BNP]) 373 promote renal sodium excretion and counteract renin-angiotensin and sympathetic nervous system activation⁴⁶. The lead variant at the *MTHFR-CLCN6* locus colocalized with *NPPA* 374 375 expression in atrial tissue, its primary site of expression. ANP (the protein product of NPPA) also plays a role in uterine decidualization and spiral artery remodeling⁴⁷, a process known to be 376 impaired in the early pathogenesis of preeclampsia^{1,10}. Furthermore, ANP is cleared from the 377 circulation by the protein product of NPR3⁴⁸, which was identified in the GWAS of gestational 378 379 hypertension. Human data also support accelerated ANP clearance in the setting of 380 preeclampsia⁴⁹. Of note, our lead risk variant at the *MTHFR-CLCN6* locus has been previously 381 associated with reduced levels of circulating N-terminal pro-BNP⁵⁰. A recent analysis from the 382 nuMoM2b cohort found that first trimester levels of N-terminal pro-BNP were unexpectedly lower 383 among women who subsequently developed HDPs later in pregnancy after adjustment for race 384 and BMI⁵¹. Collectively, these findings suggest that a relative deficiency in endogenous 385 natriuretic peptide signaling may predispose to HDPs. Synthetic natriuretic peptides have been 386 developed previously (e.g., nesiritide), and the natriuretic peptides may represent a future 387 therapeutic target for direct or indirect modulation toward HDP prevention and/or treatment. 388 Third, our findings suggest several other potential novel mechanisms underlying HDP 389 risk. Although ZNF831 has been previously associated with hypertension, the mechanisms by 390 which risk variants increase blood pressure have been unclear. In our conditional analysis at the 391 ZNF831 locus, we detected a second independent association with ZBTB46, which was also 392 strongly colocalized with the lead ZNF831 variant in multiple tissues, including arterial tissue. ZBTB46 is a transcription factor expressed in dendritic cells^{52,53} and in vascular endothelial 393

394 cells, consistent with our observed expression in aortic endothelial cells, and ZBTB46

395 overexpression suppresses endothelial cell proliferation and angiogenesis *in vitro*⁵⁴.

396 Furthermore, ZBTB46 is sensitive to shear stress⁵⁴, which may have relevance to the

397 hyperdynamic hemodynamic state of pregnancy.

398 In addition, we identified and replicated a novel association in the intergenic region 399 between PGR and TRPC6 (rs2508372), which has several plausible mechanistic links to the HDPs. Along with other newly identified HDP-associated loci (TNS2⁵⁵ and PLCE1²⁹), TRPC6 400 401 has also been linked to glomerular function. It has been implicated in focal segmental glomerulosclerosis and diabetic nephropathy⁵⁶ and mediates the proteinuria and renal 402 dysfunction induced by exposure to hypertension and diabetes⁵⁷. In addition, the progesterone 403 404 receptor mediates the physiologic response to progesterone, including pregnancy-associated vasodilation⁵⁸. As noted, ARHGAP42 (adjacent to PGR), which was found to have reduced 405 406 expression in preeclamptic placentas, regulates vascular tone and blood pressure³⁹. 407 Furthermore, this same intergenic lead variant has been associated with reduced circulating levels of matrix metalloproteinase-10⁵⁹, which mediates vascular endothelial growth factor 408 (VEGF)-induced angiogenesis⁶⁰. Further research is necessary to clarify which of these 409 410 potential mechanisms primarily mediate the preeclampsia/eclampsia risk associated with the 411 PGR/TRPC6 locus.

412 Fourth, associations at MICA and SH2B3 highlight the role of immune function in 413 preeclampsia pathogenesis. Differences in T-cell phenotypes and circulating pro- and antiinflammatory cytokines in preeclampsia are well described^{9,10}. We detected an association near 414 415 MICA (encoding major histocompatibility complex class I polypeptide-related sequence A) within 416 the HLA region, which has also been linked to multiple autoimmune diseases and may reflect 417 the importance of maternal immune tolerance of fetal cells at the maternal-fetal interface in early placentation¹⁰. Indeed, we found that preeclampsia/eclampsia PRS predicted type 1 diabetes, 418 419 celiac disease, and hypothyroidism. Subclinical thyroid dysfunction has been associated with

increased risk for preeclampsia⁶¹, and previous Finnish data suggested term preeclampsia 420 predicts incident hypothyroidism later in life⁶². SH2B3 (also known as LNK) is expressed 421 422 primarily in endothelial and hematopoietic cells and negatively regulates cytokine signaling; 423 reduced SH2B3 function has been linked to atherosclerosis as well as several autoimmune diseases⁶³. The lead variant in our preeclampsia/eclampsia GWAS at SH2B3 is in linkage 424 disequilibrium (D=0.96, $R^2=0.91$)⁶⁴ with the well-described coronary artery disease risk allele at 425 this locus (rs3184504)⁶⁵. Our lead SH2B3 variant was also associated with increased leukocyte, 426 427 red cell blood, and platelet counts in the UK Biobank (nealelab.is/uk-biobank) and with 428 heightened levels of vascular cell adhesion protein 1, platelet glycoprotein IB alpha chain, 429 interleukin-2 receptor, and lymphocyte activation gene 3 protein, among other immune-related proteins⁵⁰. Recent data indicate that reduced SH2B3 function promotes neutrophil extracellular 430 trap formation, a process implicated in preeclampsia pathogenesis^{66,67}, and arterial 431 thrombosis⁶⁸. This process was dependent on the presence of oxidized phospholipids⁶⁸, which 432 are increased in the setting of preeclampsia vs. normotensive pregnancy^{69,70}. 433 434 Fifth, we observed that polygenic risk scores for preeclampsia/eclampsia and gestational 435 hypertension were predictive in multiple external test cohorts and independent of first trimester risk indicators (blood pressure and BMI), with women in the top PRS decile demonstrating 65-436 437 85% greater risk of preeclampsia/eclampsia vs. other women. Predictive accuracy of clinical risk factors for HDPs is modest^{71,72}. Meta-analysis indicates that personal history of preeclampsia, 438 439 pre-pregnancy chronic hypertension, and pre-pregnancy diabetes are associated with relative 440 risks of 8.4, 5.1, and 3.7, respectively, for development of preeclampsia. However, nulliparity 441 carries the largest population attributable fraction of associated risk for preeclampsia (approximately one-third)¹², and most affected women lack any overt pre-pregnancy risk factors 442 other than nulliparity⁶. Low-dose aspirin after 12 weeks' gestation represents one evidence-443 444 based strategy to mitigate risk of preeclampsia and preterm birth in women at increased risk for preeclampsia⁴³. Improving pregnancy risk prediction, especially in the first pregnancy, therefore 445

remains a pressing clinical need to optimize HDP prevention^{43,73}. First trimester screening 446 447 algorithms have been developed, with the UK Fetal Medicine Foundation combined prediction 448 model⁷⁴ incorporating clinical factors, mean arterial pressure, uterine artery pulsatility index, and 449 maternal serum pregnancy-associated plasma protein A and placental growth factor being most extensively validated to date⁷⁵, although not currently endorsed by UK or US care guidelines⁴³. 450 451 Future studies are required to ascertain whether PRS may augment existing risk algorithms. In 452 contrast with markers measured during pregnancy, PRS can be calculated anytime from birth, 453 including preconception, and may therefore also inform preconception counseling and health 454 optimization.

455 Although our GWAS included substantially more non-European individuals than prior 456 GWAS, >80% of individuals were European, and as such, the preeclampsia/eclampsia and 457 gestational hypertension PRS generally performed better in European ancestry women vs. 458 others, consistent with many prior published PRS and a well-recognized challenge in contemporary genetics⁷⁶. Ongoing efforts to include accurate, detailed pregnancy and 459 460 reproductive history phenotypes in diverse genetic datasets and increase representation of non-461 European individuals will be critical to improve genetic discovery and cross-ancestry polygenic prediction and to achieve genomic equity^{76,77}. 462

This study should be considered in the context of other limitations. Due to HDP 463 464 phenotyping limitations in large datasets using ICD code-based ascertainment, some 465 participants may have had preeclampsia superimposed on chronic hypertension rather than de 466 novo preeclampsia, which may enrich genetic associations for hypertension predilection. In a 467 subset of cohorts, however, the control group included women with chronic hypertension in 468 pregnancy. Validation studies of ICD codes and registry diagnoses demonstrate that these 469 approaches have modest sensitivity but high specificity and positive predictive value (>80%) in comparison with adjudicated HDP diagnoses⁷⁸⁻⁸⁰ and that accuracy may be higher for severe vs. 470 mild preeclampsia⁸¹. We were unable to examine more granular HDP subtypes such as 471

472 preeclampsia with severe features, HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome, preterm vs. term vs. postpartum onset, or HDP with vs. without 473 474 accompanying fetal growth restriction. The underlying pathophysiology of the HDPs is 475 heterogeneous and may vary across these subtypes; future adequately powered studies should 476 examine these subtypes separately as implications for pregnancy care and long-term maternal health risk may differ⁸². In addition, we lacked paired maternal-fetal samples to condition 477 478 maternal risk variants on fetal genotype, although other complementary analyses such as 479 placental transcriptomics indicated particular variants more likely to be influencing risk via the 480 fetal genome. Finally, snRNA-seq analyses were performed in male aortic tissue; while findings 481 are consistent with current understanding of HDPs, future work is needed to verify that these 482 results are consistent in women and determine whether additional insights may be apparent in 483 women. 484 Overall, multi-ancestry genome-wide meta-analysis of preeclampsia/eclampsia and

gestational hypertension revealed novel distinct and overlapping risk loci and enabled polygenicprediction of the HDPs, with implications for HDP prediction, prevention, and treatment.

487

488 Methods

489 Study cohorts, phenotypes, genotyping, and association analysis.

490 Preeclampsia/eclampsia and gestational hypertension case and control counts and 491 definitions for each cohort are summarized in Supplementary Tables 1-3. If an individual had 492 gualifying codes for both preeclampsia/eclampsia and gestational hypertension, she was 493 designated as having preeclampsia/eclampsia. In multi-ancestry cohorts, association analyses 494 were performed within each ancestry group separately and subsequently meta-analyzed. 495 FinnGen: Cases were identified using ICD-8, -9, and -10 codes; controls were women in 496 FinnGen without codes corresponding to hypertension and/or proteinuria during pregnancy 497 (ICD-10 O10-O16). Sample genotyping in FinnGen was performed using Illumina (Illumina Inc.,

498 San Diego, CA) and Affymetrix (Thermo Fisher Scientific, Santa Clara, CA, USA) arrays. 499 Genotype calls were made using GenCall or zCall for Illumina and AxiomGT1 algorithm for Affymetrix data as described previously^{83,84}. Individuals were removed for ambiguous sex, 500 501 genotype missingness >5%, heterozygosity >±4 SD, and non-Finnish ancestry. Variants were removed for missingness >2%, Hardy-Weinberg equilibrium (HWE) P<1x10⁻⁶, and minor allele 502 503 count (MAC) <3. Pre-phasing was performed with Eagle v2.3.5 using 20,000 conditioning 504 haplotypes. Genotypes were imputed with Beagle 4.1 using the population-specific Sequencing 505 Initiative Suomi v3 imputation reference panel. Association analyses were performed using SAIGE⁸⁵ with adjustment for age, genotyping batch, and PC 1-10. 506 507 Estonian Biobank: The Estonian Biobank is a population-based biobank with over 200.000 participants⁸⁶. Preeclampsia/eclampsia cases were identified using ICD-10 O14-O15. 508 509 Gestational hypertension cases were defined using ICD-10 O13. Controls were defined using 510 ICD-10 O80-O84 and no codes for HDPs. All Estonian Biobank participants have been 511 genotyped at the Core Genotyping Lab of the Institute of Genomics, University of Tartu, using 512 the Illumina Global Screening Array v1.0, v2.0, and v2.0 EST arrays. Samples were genotyped 513 and PLINK format files were created using Illumina GenomeStudio v2.0.4. Individuals were 514 excluded from the analysis if their call-rate was <95% or if sex defined based on heterozygosity 515 of X chromosome did not match sex in phenotype data. Before imputation, variants were filtered 516 by call-rate <95%, HWE P<1x10⁻⁴, and MAF <1%. We also used the MAC filter --minMAC=5. 517 Variant positions were updated to genome build 37 and all variants were changed to be from 518 TOP strand using GSAMD-24v1-0 20011747 A1-b37.strand.RefAlt.zip files from 519 https://www.well.ox.ac.uk/~wrayner/strand/. Pre-phasing was performed with Eagle v2.3 520 software using 20,000 conditioning haplotypes, and imputation was done using Beagle 521 v.28Sep18.793 with effective population size n_e=20,000. Population specific imputation reference of 2297 WGS samples was used. Analyses were carried out with SAIGE⁸⁵, adjusting 522 523 for year of birth and PC 1-10.

524 Genes & Health: Genes & Health is a cohort of British Pakistani and Bangladeshi individuals recruited primarily in East London, England⁸⁷. Cases and parous controls were 525 526 identified using gualifying ICD-10 and SNOMED codes (Supplementary Tables 1-2). Genotyping 527 was performed using the Illumina Infinium Global Screening Array v3.0, and quality control was 528 performed using Illumina GenomeStudio and PLINK v1.9. Individuals were removed who did not 529 have Pakistani or Bangladeshi ancestry defined as $>\pm 3$ SD from the mean of PC1 and those who self-reported another ethnicity. Variants with call rate <0.99, MAF <1%, and HWE P<1x10⁻⁶ 530 531 were removed. Imputation was performed using the Michigan Imputation Server with the GenomeAsia reference panel. Association analyses were performed using SAIGE⁸⁵ with 532 adjustment for age, age², and PC 1-10. 533 534 Michigan Genomics Initiative: The Michigan Genomics Initiative enrolls participants 535 receiving care at Michigan Medicine and links biospecimen data to electronic health record 536 (EHR) data. Preeclampsia cases were identified in the freeze 3 dataset using phecode 642.1 and its corresponding ICD codes⁸⁸, and women lacking this phecode served as controls. 537 538 Genotyping was performed using one of two versions of the Illumina Infinium CoreExome-24 539 bead array platform. Relatedness within the cohort was estimated using KING v2.1.3. 540 Individuals were removed for discordant, missing, or ambiguous sex, kinship coefficient >0.45 541 with another participant, call rate <99%, estimated contamination >2.5%, or missingness on any 542 chromosome >5%. Variants were excluded with poor intensity separation based on metrics from 543 GenomeStudio (GenTrain score <0.15 or Cluster Separation score <0.3), overall call rate <99%, or HWE *P*-value $<1 \times 10^{-4}$. Genotypes were phased using EAGLE v2.4.1 and imputed using the 544 TOPMed reference panel. Association analysis was conducted using SAIGE⁸⁵ with adjustment 545 546 for age, genotype array, and PC 1-10. 547 Mass General Brigham Biobank: The Mass General Brigham Biobank is a health

system-based biobank linking genomic data to EHR data. Preeclampsia/eclampsia cases were
identified using ICD-10 O14-O15, gestational hypertension cases were identified using ICD-10

550 O13, and controls were identified using ICD-10 O80-O82. Variants with MAF <1%, missingness 551 per variant >1%, and HWE *P*-value <10⁻⁶ were removed. Imputation was performed using the 552 TOPMed reference panel. Association analysis was performed with variants filtered by MAC 553 \geq 50 and INFO score \geq 0.6 using REGENIE⁸⁹ with adjustment for age, genotype batch, and PC 1-554 10.

555 Biobank Japan: Biobank Japan is a biobank of approximately 200,000 Japanese adults. 556 Preeclampsia cases were identified using phecode 642 and its corresponding ICD codes, and other women constituted the control group⁹⁰. Genotyping was performed using the Illumina 557 558 HumanOmniExpressExome BeadChip or a combination of the Illumina HumanOmniExpress 559 and HumanExome BeadChip. Individuals with call rates <98% or closely related individuals (PI_HAT >0.175 in PLINK) were excluded. Variants with call rate <99%, HWE P<1.0x10⁻⁶, and 560 561 number of heterozygotes <5 were excluded. Genotype data were imputed with 1000 Genomes 562 Project Phase 3 v5 genotype data and Japanese whole-genome sequencing data. Association analysis was performed using SAIGE⁸⁵ with adjustment for age, age², and PC 1-20. 563

564 *BioMe:* Bio*Me* is a health system-based biobank at the Icahn School of Medicine at 565 Mount Sinai in New York, NY, USA. Preeclampsia/eclampsia and gestational hypertension 566 cases were identified using ICD-10 codes O14-O15 and O13, respectively. Controls were other 567 women enrolled in BioMe who indicated a history of childbirth on their intake questionnaire. 568 Genotyping was performed using the Illumina Global Screening Array. Individuals with ethnicity-569 specific heterozygosity rate that surpassed ± 3 SD of the population-specific mean, those with a 570 call rate of ≤95%, and those with discordance between EHR-recorded and genetic sex were 571 removed. For variant-level quality control, sites with a call rate below 95% and sites with HWE $P < 1 \times 10^{-8}$ were excluded. Imputation of variants was then performed with the Michigan 572 573 Imputation Server pipeline using the TOPMed reference panel. Association analysis was 574 performed separately in African, admixed American, and European ancestry women using SAIGE⁸⁵ with adjustment for age, age², and PC 1-10. 575

576 InterPregGen consortium: We incorporated summary statistics for preeclampsia from the discovery GWAS meta-analyses of European cohorts and Central Asian cohorts from the 577 InterPregGen consortium¹⁷. European-ancestry discovery cohorts included GOPEC (United 578 579 Kingdom), deCODE (Iceland), the Avon Longitudinal Study of Parents and Children (United Kingdom), MoBa (Norway), SSI (Denmark), and FINRISK (Finland) (7,219 cases and 155,620 580 581 controls). Central Asian cohorts included two Kazakh cohorts and one Uzbek cohort (2,296 582 cases and 2,059 controls). Cohort-specific preeclampsia and control definitions are summarized 583 in Supplementary Table 3¹⁷. Fixed-effects inverse variance-weighted meta-analysis was performed in METAL²³. 584

585 HUNT: The HUNT study is a population-based cohort study in Nord-Trøndelag County, 586 Norway. Genotyped, parous, European-ancestry women were included in the present analysis. 587 Preeclampsia/eclampsia was ascertained by linkage to the Medical Birth Registry of Norway, 588 which defines preeclampsia as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure \geq 90 mmHg accompanied by proteinuria >0.3 g/24 h or >1+ on urine dipstick⁹¹. The 589 590 current analysis includes genetic data from approximately 90% of participants from HUNT2 591 (1995-1997) and HUNT3 (2006-2008) who were genotyped by genome-wide SNP arrays in 2015^{92,93}. Genotyping, quality control metrics, and imputation have been described previously⁹². 592 593 Briefly, one of three different Illumina HumanCoreExome arrays (HumanCoreExome12 v1.0, 594 HumanCoreExome12 v1.1, and UM HUNT Biobank v1.0) were used for genotyping the HUNT2 595 and HUNT3 samples⁹². Samples and variants with call rate <99% were excluded. Imputation 596 was performed using 2.201 HUNT samples with whole genome sequencing, the Haplotype 597 Reference Consortium, and TOPMed imputation panel (MAC >10). Association analysis was performed using SAIGE⁸⁵ with adjustment for age, age², and PC 1-10. 598

599 UK Biobank: The UK Biobank is a population-based cohort study of adult residents of
600 the UK aged 40-69 years at the time of recruitment between 2006-2010.

601 Preeclampsia/eclampsia and gestational hypertension cases were identified using qualifying

602	ICD codes (Supplementary Table 1); controls were women self-reporting a history of at least
603	one live birth at the time of study enrollment without qualifying ICD codes for
604	preeclampsia/eclampsia or gestational hypertension or any self-reported history of HDPs.
605	Genotyping was performed using the UK BiLEVE Axiom Array or the UK Biobank Axiom Array
606	(both Affymetrix, Santa Clara, CA). Individuals with single nucleotide variant missingness ≥10%
607	were excluded. Imputation was performed centrally using the Haplotype Reference Consortium,
608	UK10K, and 1000 Genome reference panels ⁹⁴ . Variants were required to pass the following
609	quality control filters: MAF \geq 1%, single nucleotide variant missingness <10%, and HWE $P \geq$ 10 ⁻¹⁵ ,
610	MAC ≥50, and INFO score ≥0.6. Association analysis was performed in European-ancestry
611	participants using REGENIE ⁸⁹ with adjustment for age, genotyping array, and PC 1-10.
612	Penn Medicine Biobank (PMBB): PMBB is a health system-based biobank at the
613	University of Pennsylvania, Philadelphia, PA, USA. Preeclampsia/eclampsia cases were
614	identified using ICD-10 codes O14-O15 or phecode 642.1. Gestational hypertension cases were
615	identified using ICD-10 code O13. Controls were other women enrolled in PMBB. Genotyping
616	was performed using the Illumina Global Sequencing Array v2.0; genotype data were imputed to
617	the TOPMed reference panel using the Michigan Imputation Server. Variants with MAF<1%,
618	missing rate >10%, and HWE P <10 ⁻⁸ were filtered from the GWAS. Association analysis was
619	performed in REGENIE separately for African-ancestry and European-ancestry women with
620	adjustment for age, age ² , and PC 1-5.
621	nuMoM2b: The nuMoM2b study is a prospective U.S. pregnancy cohort of nulliparous
622	women enrolled in the first trimester of pregnancy between 2012-2015. HDPs were determined
623	by chart abstraction and adjudication according to previously published definitions ⁹⁵ .

624 Gestational hypertension was defined as SBP ≥140 mmHg or DBP ≥90 mmHg on two

625 occasions \geq 6 hours apart or one occasion with subsequent antihypertensive therapy after 20

- 626 weeks' gestation, excluding blood pressures recorded during the second stage of labor, without
- other qualifying features for preeclampsia or eclampsia. Preeclampsia was defined according to

628 the same blood pressure criteria plus proteinuria or other findings meeting criteria for severe features, including HELLP syndrome⁹⁵. Women documented as meeting these same blood 629 pressure criteria before 20 weeks' gestation were designated as having chronic hypertension. 630 631 All women were at risk for development of preeclampsia/eclampsia; only those without chronic 632 hypertension were at risk for the outcome of gestational hypertension. Blood pressure and BMI 633 were recorded at the first trimester study visit, which occurred at a mean (SD) 11.6 (1.5) weeks' 634 gestation. Genotyping was performed using the Illumina Infinium Multi-Ethnic Global D2 635 BeadChip. Individuals related within two degrees by the KING algorithm were removed. Variants with MAF <1%, genotyping rate <95%, and HWE P<5x10⁻⁶ were removed⁹⁶. After phasing with 636 637 EAGLE, imputation was performed for European, African, and admixed American ancestry 638 subjects using the TOPMed reference panel via the TOPMed Imputation Server. Association 639 analysis was performed in REGENIE separately by ancestry group (European, African, and 640 admixed American) with adjustment for age and PC 1-10. The same women in nuMoM2b with 641 imputed genotypes were used for external testing of optimized PRS (described below). 642

643 Genome-wide meta-analysis and replication.

644 Variants from GWAS summary statistics were matched by genome build 38 position and 645 alleles. GWAS summary statistics that were in genome build 37 were lifted to genome build 38 646 using UCSC liftOver (https://genome.ucsc.edu/cgi-bin/hgLiftOver). We used METAL²³ to 647 perform fixed-effect inverse variance-weighted meta-analysis. Correction for genomic inflation 648 factor was carried out prior to meta-analysis. Meta-analyses were conducted among discovery 649 cohorts, among follow-up cohorts, and across all cohorts. Given the potential overlap of 400 650 preeclampsia/eclampsia cases from FINRISK between the InterPregGen meta-analysis and 651 FinnGen (8.4% of FinnGen cases and 2.3% of overall discovery cases) and 7,805 controls 652 (5.7% of FinnGen controls and 1.7% of overall discovery controls), we conducted a sensitivity 653 analysis excluding FinnGen (Supplementary Table 4).

Lead variants for preeclampsia/eclampsia and gestational hypertension were interrogated in multi-ancestry meta-analysis of follow-up cohorts using METAL: HUNT (preeclampsia/eclampsia only), UK Biobank, PMBB (European- and African-ancestry women), and nuMoM2b (European-, African-, and admixed American-ancestry women). P<0.05 in followup cohorts, consistent direction of effect in follow-up cohorts, and genome-wide significance (P<5x10⁻⁸) in combined meta-analysis of discovery and follow-up cohorts indicated replication.

660

661 Conditional and joint analysis.

We conducted conditional analysis using GCTA-COJO²⁴ on the multi-ancestry meta-662 663 analyses of preeclampsia/eclampsia and gestational hypertension to identify additional 664 association signals at the genome-wide significant loci. We used the European LD reference 665 from a randomly selected set of 10,000 unrelated individuals. The LD panel included variants 666 with MAF > 1% and INFO \ge 0.3. The analysis was restricted to variants within ±1 Mb from lead 667 variants ($P < 5x10^{-8}$). In COJO, the lead variants were conditioned from each chromosome and 668 independent variants were iteratively included. All variants were then simultaneously fitted in the joint analysis. Variants with $P < 2 \times 10^{-7}$ were considered genome-wide significant. One additional 669 variant with conditional $P < 2 \times 10^{-7}$ for association with preeclampsia/eclampsia was identified on 670 chromosome 20 ($P=1.4x10^{-8}$). 671

672

673 Genetic correlation.

We used LD score regression (LDSC, <u>https://github.com/bulik/ldsc</u>)²⁵ with pre-computed LD scores for 1.2 million HapMap3 variants after excluding MHC region in the European population (<u>https://data.broadinstitute.org/alkesgroup/LDSCORE/eur w ld chr.tar.bz2</u>) to calculate genetic correlation between preeclampsia/eclampsia and gestational hypertension and correlation of each HDP with systolic and diastolic blood pressure. In addition, the LDSC intercept indicates potential confounding due to potential population stratification and cryptic

680	relatedness.	In combined	meta-analysi	s of discovery	y and follow-up	o cohorts,	we observed
-----	--------------	-------------	--------------	----------------	-----------------	------------	-------------

- 681 intercepts of 1.03 for preeclampsia/eclampsia and 0.95 for gestational hypertension.
- 682

683 Colocalization analysis.

684 We obtained the tissue-specific gene expression from GTEx data portal for 52 tissues³².

685 We used marginal effect sizes, standard errors, and MAF for all SNPs within ±500 of lead

variants from discovery analysis ($P < 5 \times 10^{-8}$) as the input. We performed colocalization using the

687 coloc.abf() function in R package coloc v4. The H₄ test statistic estimates the posterior

688 probability of a shared causal variant between preeclampsia/eclampsia or gestational

689 hypertension and expression of a particular gene. H₄ >0.7 indicated strong evidence of

690 colocalization, H₄ 0.5-<0.7 indicated weak evidence of colocalization, and H₄ <0.5 indicated no

691 colocalization.

692

693 Polygenic prioritization of causal genes.

We performed additional causal gene prioritization using the PoPS method³⁴. Briefly, 694 695 PoPS integrates GWAS summary statistics with gene expression, biology pathways, and 696 predicted protein-protein interaction data to identify likely causal genes at genome-wide 697 significant loci. A linear model was trained to predict gene-level association scores and estimate 698 Z-scores indicating the confidence of the causal role at a given locus. In total, PoPS scores 699 were calculated for 18,000 genes. The top 5 available prioritized genes within 500 kilobases of 700 lead preeclampsia/eclampsia and gestational hypertension variants were extracted and 701 compared with the results of other in silico analyses.

702

703 Placental transcriptome data.

Genes nearest to lead variants, colocalization hits, and genes prioritized within the top 5
by either Open Targets variant-to-gene score or PoPS score were queried in a publicly available

database of placental gene expression (https://www.obgyn.cam.ac.uk/placentome/)³⁵. Samples 706 were obtained from a prospective cohort of nulliparous women in Cambridge, United Kingdom. 707 708 Differential expression analysis for preeclampsia included 82 preeclampsia cases and 82 709 controls samples matched on presence of labor, Cesarean section, gestational age, fetal sex, 710 smoking status, maternal BMI, and maternal age. RNA sequencing was performed on placental 711 biopsy specimens with a median sequencing depth of 101 million reads per sample. Differential 712 expression (in log₂-fold change) and corresponding P-values were generated using DESeq2; P-713 values were then adjusted for multiple comparisons using the Benjamini-Hochberg method. We 714 report differentially expressed prioritized genes with adjusted *P* < 0.05 (Supplementary Table 715 14).

716

717 Gene expression in human aortic tissue.

718 We queried expression of prioritized genes in subpopulations of vascular smooth muscle 719 cells, fibromyocytes, fibroblasts, endothelial cells, macrophages, natural killer T cells, and 720 neuronal cells in a dataset of single-nuclei RNA sequencing from human aortic tissue. In total, 721 1,114 unique molecular identifiers were obtained per cell. Prioritized genes were nearest genes, 722 genes with strong colocalization, genes with weak colocalization plus prioritization by another 723 method (top 5 Open Targets variant-to-gene score or PoPS), and genes prioritized by another 724 method plus statistically significant differential placental transcription in the human placental transcriptome browser³⁵'; of these genes, 24 were available in the single-nuclei RNA 725 726 sequencing dataset (Extended Data Fig. 3). Single-nuclei RNA sequencing was performed on 727 non-atherosclerotic aortic root tissue from two individuals obtained during coronary artery 728 bypass graft surgery. Both individuals contributing aortic tissue specimens were European-729 ancestry men, aged 49 and 51 years, with hypertension, hypercholesterolemia, and coronary 730 artery disease. Both were using aspirin and a statin preoperatively. A total of 4,537 nuclei were 731 obtained for downstream analysis. Cell types and subtypes were defined using top marker

732 genes and pathway enrichment scores. Raw Cellranger output data were filtered for removal of 733 ambient RNA using *cellbender* in 'full' running mode. The resultant filtered cell-gene matrix was 734 used for quality control and downstream analysis. All preliminary quality-control and clustering 735 were performed using scanpy. Any cells with fewer than 300 genes captured or greater than 736 0.1% mitochondrial reads were excluded from the analysis. Each sample was processed 737 with Scrublet to exclude doublets. The top 10,000 variable genes were used for 738 analysis. Relative expression of queried genes in each cell type against other cell types in 739 normal aortic tissue was quantified as Z-scores.

740

741 Derivation and testing of genome-wide polygenic risk scores.

742 We used PRS-CS to derive genome-wide PRS for preeclampsia/eclampsia and 743 gestational hypertension from the corresponding discovery GWAS summary statistics and for 744 systolic blood pressure from the Million Veteran Program GWAS summary statistics²⁶. PRS-CS 745 is a Bayesian approach that estimates posterior effect sizes by placing a continuous shrinkage prior on variant effect sizes⁴¹. The preeclampsia/eclampsia PRS included 1,087,033 HapMap3 746 747 variants, the gestational hypertension PRS included 1,087,916 HapMap3 variants, and the SBP 748 PRS included 1,064,898 HapMap3 variants. PRS were trained on the UK Biobank European LD 749 panel. Individual-level polygenic scores were generated in the tuning and test datasets as the 750 sum of genotypes*weights using PLINK. We used logistic regression to test the association of 751 each PRS with preeclampsia/eclampsia and gestational hypertension with adjustment for age, 752 age², and PC 1-10. PRS were tuned in the UK Biobank. Specifically, we used a small-scale grid search of global shrinkage parameter \Box values (1, 1x10⁻², 1x10⁻⁴, and 1x10⁻⁶) for each PRS as 753 754 recommended to identify the
that produced the best predictive performance as measured by 755 R^2 in the tuning dataset. We then fitted a linear combination of optimized 756 preeclampsia/eclampsia PRS and SBP PRS for the outcome of preeclampsia/eclampsia and a

757 linear combination of gestational hypertension PRS and SBP PRS for the outcome of

gestational hypertension. The optimal linear combination derived for preeclampsia/eclampsia was $0.1889^*Z_{preeclampsia/eclampsia} + 0.1864^*Z_{SBP}$, and the linear combination derived for gestational hypertension was $0.1662^*Z_{gestational_hypertension} + 0.3050^*Z_{SBP}$. We then carried these weighed linear combination scores forward for final testing in nuMoM2b (European, African, and admixed American ancestry groups) and HUNT (European ancestry). PRS performance was evaluated using the OR for top decile vs. bottom 90% of PRS, the OR per SD of PRS, and Nagelkerke's R^2 .

765 We tested whether PRS correctly re-classified nuMoM2b participants with HDPs as 766 aspirin-eligible in comparison with the major criteria endorsed by the U.S. Preventive Services Task Force⁴³. Major criteria include: history of preeclampsia, which does not apply in nuMoM2b 767 768 as all women were nulliparous; multifetal gestation, which does not apply in nuMoM2b as all 769 women had singleton pregnancies; chronic hypertension, defined as a diagnosis of 770 hypertension before pregnancy or blood pressure \geq 140/90 mmHg on two occasions at least 6 771 hours apart prior to 20 weeks' gestation; pre-gestational diabetes type 1 or type 2; any pre-772 pregnancy kidney disease; and autoimmune disease, defined here as antiphospholipid antibody 773 syndrome, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease 774 (Crohn's disease or ulcerative colitis), or "other collagen vascular or autoimmune disease." We 775 calculated sensitivity, specificity, positive predictive value, and negative predictive value for 776 major risk factors with or without different thresholds for PRSpreeclampsia+SBP for the prediction of 777 preeclampsia/eclampsia, as well as net reclassification for composite HDPs vs. normotensive 778 pregnancy and for preeclampsia/eclampsia vs. all other pregnancies. Confidence intervals for 779 sensitivity, specificity, positive predictive value, and negative predictive value were calculated 780 using the normal approximation. Given use of PRS to up-classify risk, net reclassification was 781 calculated as P(up|case) - P(up|non-case). Bootstrap resampling performed 1,000 times was 782 used to estimate 95% confidence intervals for net reclassification.

783

784 Phenome-wide association analysis.

We tested the association of preeclampsia/eclampsia PRS and gestational hypertension PRS with 1,445 phecode-based combined prevalent and incident phenotypes⁹⁷ in sex-stratified fashion among genotyped UK Biobank participants with adjustment for age and PC 1-5 using the PheWAS package⁹⁸ in R 3.6.0 (<u>https://github.com/PheWAS/PheWAS</u>). Bonferroni-corrected $P<0.05/1,445 = 3.5x10^{-5}$ indicated statistical significance.

790

791 Ethics approval.

792 FinnGen was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa 793 Hospital District. The Estonian Committee on Bioethics gave ethical approval for the work 794 conducted in the Estonian Biobank. The South East Research Ethics Committee gave ethical 795 approval for the work conducted in Genes & Health. The University of Michigan Medical School 796 Institutional Review Board gave ethical approval for the analyses conducted in the Michigan 797 Genomics Initiative. The Mass General Brigham Institutional Review Board gave ethical 798 approval for the work conducted in the Mass General Brigham Biobank. Biobank Japan 799 received ethics approval from the Institute of Medical Science, the University of Tokyo, the 800 RIKEN Yokohama Institute, and all participating hospitals. BioMe received ethics approval from 801 the Icahn School of Medicine at Mt. Sinai Institutional Review Board. We used publicly available 802 summary statistics for discovery GWAS from the InterPregGen consortium; all contributing studies received ethics approval as reported previously¹⁷. The work conducted in HUNT was 803 804 approved by the Regional Committee for Ethics in Medical Research, Norway (2018/2488). The 805 Penn Medicine Biobank received ethics approval from the University of Pennsylvania 806 Institutional Review Board. The North West Multi-centre Research Ethics Committee approved 807 the UK Biobank; the Mass General Brigham Institutional Review Board approved secondary 808 data analyses of the UK Biobank (application #7089). The nuMoM2b study was approved by the

809 institutional review boards of each participating site. All participants in all studies contributing

810 data for this study signed informed consent for participation and the use of data in research.

811 References

812 1. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and 813 clinical implications. *BMJ*. **366**, I2381 (2019)

Jiang L, et al. A global view of hypertensive disorders and diabetes mellitus during
 pregnancy. *Nat Rev Endocrinol.* 18, 760-775 (2022).

816 3. Garovic VD, et al. Incidence and Long-Term Outcomes of Hypertensive Disorders of
 817 Pregnancy. *J Am Coll Cardiol.* 18, 2323-2334 (2020).

818 4. Fraser A, et al. Associations of pregnancy complications with calculated cardiovascular

disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of
Parents and Children. *Circulation*. **125**, 1367-1380 (2012).

821 5. Magee LA, et al. The 2021 International Society for the Study of Hypertension in
822 Pregnancy classification, diagnosis & management recommendations for international practice.
823 *Pregnancy Hypertens.* 27, 148-169 (2022).

6. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. *Obstet Gynecol.* **133**, e1-e25 (2019).

826 7. Honigberg MC, et al. Long-Term Cardiovascular Risk in Women With Hypertension
827 During Pregnancy. *J Am Coll Cardiol.* 74, 2743-2754 (2019).

828 8. Wang YX, et al. Hypertensive Disorders of Pregnancy and Subsequent Risk of 829 Premature Mortality. *J Am Coll Cardiol.* **77**, 1302-1312 (2021).

830 9. Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-Pathophysiology and 831 Clinical Presentations: JACC State-of-the-Art Review. *J Am Coll Cardiol.* **76**, 1690-1702 (2020).

832 10. Rana S, Lemoine E, Granger J, Karumanchi SA. Preeclampsia. *Circ Res.* 124, 1094833 1112 (2019).

Levine RJ, et al. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med.* **350**, 672-683 (2004).

836 12. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia

determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ.* 353, i1753 (2016).

13. Jung E, et al. The etiology of preeclampsia. *Am J Obstet Gynecol.* **226**, S844-S866 (2022).

14. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors
account for most of familial aggregation of preeclampsia: a population-based Swedish cohort
study. *Am J Med Genet A.* **130**, 365-371 (2004).

Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and
environmental effects for pre-eclampsia and gestational hypertension: a family study. *BJOG*.
111, 200-206 (2004).

847 16. McGinnis R, et al. Variants in the fetal genome near FLT1 are associated with risk of 848 preeclampsia. *Nat Genet.* **49**, 1255-1260 (2017).

849 17. Steinthorsdottir V, et al. Genetic predisposition to hypertension is associated with 850 preeclampsia in European and Central Asian women. *Nat Commun.* **11**, 5976 (2020).

851 18. Dina C, et al. Variation in FTO contributes to childhood obesity and severe adult obesity. 852 *Nat Genet.* **39**, 724-726 (2007).

Honigberg MC, et al. Genetic Variation in Cardiometabolic Traits and Medication Targets
and the Risk of Hypertensive Disorders of Pregnancy. *Circulation*. **142**, 711-713 (2020).

855 20. Gray KJ, et al. Risk of pre-eclampsia in patients with a maternal genetic predisposition to 856 common medical conditions: a case-control study. *BJOG*. **128**, 55-65 (2021).

21. O'Kelly AC, et al. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res.* **130**, 652-672 (2022).

859 22. Kivioja A, Toivonen E, Tyrmi J, et al. Increased Risk of Preeclampsia in Women With a 860 Genetic Predisposition to Elevated Blood Pressure. *Hypertension*. **79**, 2008-2015 (2022).

- 861 23. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide 862 association scans. *Bioinformatics*. **26**, 2190-2191 (2010.
- 24. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet.* **88**, 76-82 (2011).
- 865 25. Bulik-Sullivan BK, et al. LD Score regression distinguishes confounding from
- polygenicity in genome-wide association studies. *Nat Genet.* 47, 291-295, 2015.
- 867 26. Giri A, et al. Trans-ethnic association study of blood pressure determinants in over
 868 750,000 individuals. *Nat Genet.* 51, 51-62 (2019).
- 869 27. Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. 870 *Nat Genet.* **47**, 1236-1241 (2015).
- 871 28. Turley P, et al. Multi-trait analysis of genome-wide association summary statistics using 872 MTAG. *Nat Genet.* **50**, 229-237 (2018).
- 873 29. Padmanabhan S, Caulfield M, Dominiczak AF. Genetic and molecular aspects of 874 hypertension. *Circ Res.* **116**, 937-959 (2015).
- 875 30. Rubattu S, Forte M, Marchitti S, Volpe M. Molecular Implications of Natriuretic Peptides
 876 in the Protection from Hypertension and Target Organ Damage Development. *Int J Mol Sci.* 20,
 877 798 (2019).
- 878 31. Ohwaki A, Nishizawa H, Kato A, et al. Altered serum soluble furin and prorenin receptor 879 levels in pregnancies with pre-eclampsia and fetal growth restriction. *J Gynecol Obstet Hum*
- *Reprod.* 50, 102198 (2021).
 32. Battle A, et al. Genetic effects on gene expression across human tissues. *Nature.* 550, 204-213 (2017).
- 33. Ghoussaini M, et al. Open Targets Genetics: systematic identification of trait-associated
 genes using large-scale genetics and functional genomics. *Nucleic Acids Res.* 49, D1311D1320 (2021).
- Weeks EM, et al. Leveraging polygenic enrichments of gene features to predict genes
 underlying complex traits and diseases. Preprint at
- 888 https://www.medrxiv.org/content/10.1101/2020.09.08.20190561v1 (2020).
- 889 35. Gong S, et al. The RNA landscape of the human placenta in health and disease. *Nat* 890 *Commun.* **12**, 2639 (2021).
- 891 36. Maynard SE, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may
- contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest.* 111, 649-658 (2003).
- 894 37. Tekola-Ayele F, et al. Placental multi-omics integration identifies candidate functional 895 genes for birthweight. *Nat Commun.* **13**, 2384 (2022).
- 896 38. Zhang Z, Wang X, Zhang L, Shi Y, Wang J, Yan H. Wnt/β-catenin signaling pathway in
 897 trophoblasts and abnormal activation in preeclampsia (Review). *Mol Med Rep.* 16, 1007-1013
 898 (2017).
- 899 39. Bai X, Lenhart KC, Bird KE, et al. The smooth muscle-selective RhoGAP GRAF3 is a critical regulator of vascular tone and hypertension. *Nat Commun.* **4**, 2910 (2013).
- 40. Kalluri AS, et al. Single-Cell Analysis of the Normal Mouse Aorta Reveals Functionally
 Distinct Endothelial Cell Populations. *Circulation*. **140**, 147-163 (2019).
- 903 41. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian 904 regression and continuous shrinkage priors. *Nat Commun.* **10**, 1776 (2019).
- Ray JG, Abdulaziz KE, Berger H. Aspirin Use for Preeclampsia Prevention Among
 Women With Prepregnancy Diabetes, Obesity, and Hypertension. JAMA. 327, 388-390 (2022).
- 907 43. Davidson KW, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and
- 908 Mortality: US Preventive Services Task Force Recommendation Statement. *JAMA*. **326**, 1186-909 1191 (2021).
- 910 44. Pollheimer J, et al. Activation of the canonical wingless/T-cell factor signaling pathway 911 promotes invasive differentiation of human trophoblast. *Am J Pathol.* **168**, 1134-1147 (2006).

912 45. Tita AT, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med. 913 386, 1781-1792 (2002). 914 46. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 50, 2357-2368 (2007). 915 47. Zhang W, et al. Atrial natriuretic peptide promotes uterine decidualization and a TRAIL-916 dependent mechanism in spiral artery remodeling. J Clin Invest. 131, e151053 (2021). 917 Maack T, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 48. 918 **238**, 675-678 (1987). 919 Gu Y, et al. Aberrant pro-atrial natriuretic peptide/corin/natriuretic peptide receptor 49. 920 signaling is present in maternal vascular endothelium in preeclampsia. Pregnancy Hypertens. 921 **11**, 1-6 (2018). 922 Sun BB, et al. Genomic atlas of the human plasma proteome. Nature. 558, 73-79 (2018). 50. 923 51. Hauspurg A, et al. Association of N-Terminal Pro-Brain Natriuretic Peptide Concentration 924 in Early Pregnancy With Development of Hypertensive Disorders of Pregnancy and Future 925 Hypertension. JAMA Cardiol. 7, 268-276 (2022). 926 Satpathy AT, et al. Zbtb46 expression distinguishes classical dendritic cells and their 52. 927 committed progenitors from other immune lineages. J Exp Med. 209, 1135-1152 (2012). 928 53. Meredith MM, et al. Zinc finger transcription factor zDC is a negative regulator required 929 to prevent activation of classical dendritic cells in the steady state. J Exp Med. 209, 1583-1593 930 (2012). 931 54. Wang Y, Sun HY, Kumar S, Puerta MDM, Jo H, Rezvan A. ZBTB46 is a shear-sensitive 932 transcription factor inhibiting endothelial cell proliferation via gene expression regulation of cell 933 cycle proteins. Lab Invest. 99, 305-318 (2019). 934 Ashraf S, et al. Mutations in six nephrosis genes delineate a pathogenic pathway 55. 935 amenable to treatment. Nat Commun. 9, 1960 (2018). 936 56. Hall G, Wang L, Spurney RF. TRPC Channels in Proteinuric Kidney Diseases. Cells. 9, 937 44 (2019). 938 Wang Z, et al. Transient receptor potential cation channel 6 contributes to kidney injury 57. 939 induced by diabetes and hypertension. Am J Physiol Renal Physiol. 322, F76-F88 (2022). 940 Pang Y, Dong J, Thomas P. Progesterone increases nitric oxide synthesis in human 58. 941 vascular endothelial cells through activation of membrane progesterone receptor-a. Am J 942 Physiol Endocrinol Metab. 308, E899-911 (2015). 943 Folkersen L, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 59. 944 30,931 individuals. Nat Metab. 2, 1135-1148 (2020). 945 Heo SH, Choi YJ, Ryoo HM, Cho JY. Expression profiling of ETS and MMP factors in 60. 946 VEGF-activated endothelial cells: role of MMP-10 in VEGF-induced angiogenesis. J Cell 947 Physiol. 224, 734-742 (2010). 948 Toloza FJK, et al. Association between maternal thyroid function and risk of gestational 61. 949 hypertension and pre-eclampsia: a systematic review and individual-participant data meta-950 analysis. Lancet Diabetes Endocrinol. 10, 243-252 (2022). 951 Männistö T, et al. Preeclampsia, gestational hypertension and subsequent 62. 952 hypothyroidism. Pregnancy Hypertens. 3, 21-27 (2013). 953 Wang W, et al. LNK/SH2B3 Loss of Function Promotes Atherosclerosis and Thrombosis. 63. 954 *Circ Res.* **119**, e91-e103 (2016). 955 Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-64. 956 specific haplotype structure and linking correlated alleles of possible functional variants. 957 *Bioinformatics.* **31**, 3555-3557 (2015). 958 Deloukas P, et al. Large-scale association analysis identifies new risk loci for coronary 65. 959 artery disease. Nat Genet. 45, 25-33 (2013). 960 Gupta AK, Hasler P, Holzgreve W, Hahn S. Neutrophil NETs: a novel contributor to 66. 961 preeclampsia-associated placental hypoxia? Semin Immunopathol. 29, 163-167 (2007).

962 67. Palomo M, et al. Differences and similarities in endothelial and angiogenic profiles of 963 preeclampsia and COVID-19 in pregnancy. *Am J Obstet Gynecol.* **227**, e1-e16 (2022).

964 68. Dou H, et al. Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in
 965 LNK(SH2B3) Deficiency. *Circulation*. 144, 1940-1954 (2021).

966 69. Anand S, et al. Detection and confirmation of serum lipid biomarkers for preeclampsia 967 using direct infusion mass spectrometry. *J Lipid Res.* **57**, 687-696 (2016).

968 70. He B, Liu Y, Maurya MR, et al. The maternal blood lipidome is indicative of the 969 pathogenesis of severe preeclampsia. *J Lipid Res.* **62**, 100118 (2021).

970 71. Wright D, Syngelaki A, Akolekar R, Poon LC, Nicolaides KH. Competing risks model in

971 screening for preeclampsia by maternal characteristics and medical history. *Am J Obstet*972 *Gynecol.* 213, e1-e10 (2015).

- 973 72. Al-Rubaie ZTA, et al. Prediction of pre-eclampsia in nulliparous women using routinely
 974 collected maternal characteristics: a model development and validation study. *BMC Pregnancy*975 *Childbirth.* 20, 23 (2020).
- 976 73. Myatt L. The prediction of preeclampsia: the way forward. *Am J Obstet Gynecol.* **226**, 977 S1102-S1107 (2022).
- 978 74. Akolekar R, Śyngelaki A, Poon L, Wright D, Nicolaides KH. Competing risks model in
- 979 early screening for preeclampsia by biophysical and biochemical markers. *Fetal Diagn Ther.* 33,
 980 8-15 (2013).
- 981 75. Chaemsaithong P, Sahota DS, Poon LC. First trimester preeclampsia screening and 982 prediction. *Am J Obstet Gynecol.* **226**, S1071-S1097 (2022)
- 983 76. Martin AR, Kanai M, Kamatani Y, Okada Y, Neale BM, Daly MJ. Clinical use of current 984 polygenic risk scores may exacerbate health disparities. *Nat Genet.* **51**, 584-591 (2019).
- 985 77. Graham SE, Clarke SL, Wu KH, et al. The power of genetic diversity in genome-wide 986 association studies of lipids. *Nature*. **600**, 675-679 (2021).

987 78. Angras K, Boyd VE, Gray C, Young AJ, Paglia MJ, Mackeen AD. Retrospective
988 application of algorithms to improve identification of pregnancy outcomes from the electronic
989 health record. *J Perinatol.* 43, 10-14 (2023).

990 79. Klungsøyr K, Harmon QE, Skard LB, et al. Validity of pre-eclampsia registration in the 991 medical birth registry of norway for women participating in the norwegian mother and child 992 cohort study, 1999-2010. *Paediatr Perinat Epidemiol.* **28**, 362-371 (2014).

- 80. Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of preeclampsia-related
 diagnoses recorded in a national hospital registry and in a postpartum interview of the women. *Am J Epidemiol.* 166, 117-124 (2007).
- 996 81. Geller SE, Ahmed S, Brown ML, Cox SM, Rosenberg D, Kilpatrick SJ. International
- 997 Classification of Diseases-9th revision coding for preeclampsia: how accurate is it? *Am J Obstet* 998 *Gynecol.* **190**, 1629-1633 (2004).

999 82. Roberts JM, Rich-Edwards JW, McElrath TF, Garmire L, Myatt L. Subtypes of 1000 Preeclampsia: Recognition and Determining Clinical Usefulness. **77**, 1430-1441 (2021).

- 1001 83. Kurki MI, et al. FinnGen provide genetic insights from a well-phenotyped isolated 1002 population. *Nature*. **613**, 508-518 (2023).
- 1003 84. Sun BB, et al. Genetic associations of protein-coding variants in human disease. *Nature*. 1004 **603**, 95-102 (2022).
- 1005 85. Zhou W, et al. Efficiently controlling for case-control imbalance and sample relatedness 1006 in large-scale genetic association studies. *Nat Genet.* **50**, 1335-1341 (2018).
- 1007 86. Leitsalu L, et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, 1008 University of Tartu. Int J Epidemiol. **44**, 1137-1147 (2015).
- 1009 87. Finer S, et al. Cohort Profile: East London Genes & Health (ELGH), a community-based
- 1010 population genomics and health study in British Bangladeshi and British Pakistani people. Int J
- 1011 *Epidemiol.* **49**, 20-21 (2020).

- 1012 88. Wei WQ, et al. Evaluating phecodes, clinical classification software, and ICD-9-CM
- 1013 codes for phenome-wide association studies in the electronic health record. *PLoS One.* 12,
 1014 e0175508 (2017).
- 1015 89. Mbatchou J, et al. Computationally efficient whole-genome regression for quantitative 1016 and binary traits. *Nat Genet.* **53**, 1097-1103 (2021).
- 1017 90. Sakaue S, et al. A cross-population atlas of genetic associations for 220 human 1018 phenotypes. *Nat Genet.* **53**, 1415-1424 (2021).
- 1019 91. Honigberg MC, et al. Heart Failure in Women With Hypertensive Disorders of
- 1020 Pregnancy: Insights From the Cardiovascular Disease in Norway Project. *Hypertension*. **76**, 1021 1506-1513 (2020).
- Brumpton BM, et al. The HUNT study: A population-based cohort for genetic research. *Cell Genomics.* 2, 100193 (2022).
- 1024 93. Åsvold BO, et al. Cohort Profile Update: The HUNT Study, Norway. *International Journal* 1025 of *Epidemiology*. **52**, e80-e91 (2023).
- 1026 94. Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. 1027 *Nature*. **562**, 203-209 (2018).
- 1028 95. Facco FL, et al. Association Between Sleep-Disordered Breathing and Hypertensive
- 1029 Disorders of Pregnancy and Gestational Diabetes Mellitus. Obstet Gynecol. 129, 31-41 (2017).
- 1030 96. Guerrero RF, et al. Genetic Polymorphisms Associated with Adverse Pregnancy
- 1031 Outcomes in Nulliparas. Preprint available at
- 1032 https://www.medrxiv.org/content/10.1101/2022.02.28.22271641v1.
- 1033 97. Denny JC, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. *Bioinformatics*. **26**, 1205-1210 (2010).
- 1035 98. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for
- 1036 phenome-wide association studies in the R environment. *Bioinformatics*. **30**, 2375-2376 (2014). 1037

1038 Data availability

- 1039 Upon publication, GWAS summary statistics for preeclampsia/eclampsia and gestational
- 1040 hypertension will be made publicly available through the Broad Institute CVDi portal, and
- 1041 corresponding genome-wide polygenic scores will be posted to the PGS Catalog. Summary
- 1042 statistics used in this meta-analysis are publicly available for FinnGen r6
- 1043 (https://www.finngen.fi/en/access_results) and for BioBank Japan
- 1044 (https://pheweb.jp/pheno/PreEclampsia). Summary statistics from the InterPregGen consortium
- 1045 are available at <u>https://ega-archive.org</u>. Placental transcriptome data are publicly available at
- 1046 <u>https://www.obgyn.cam.ac.uk/placentome/.</u>
- 1047

1048 Code availability

- 1049 The code used to conduct these analyses is available at https://github.com/buutrg/HDP.
- 1050

1051 Acknowledgements

- 1052 This work was supported by grants from the U.S. National Heart Lung and Blood Institute
- 1053 K08HL166687 (M.C.H.), K08HL146963 (K.J.G.), R01 HL163234 (R.S., K.J.G.), R01HL139865
- 1054 (R.D.), R01HL155915 (R.D.), DP2HL152423 (R.M.G.), U01HL166060 (R.M.G.), R03HL148483
- 1055 (R.M.G.), R01HL142711 (P.N.), R01HL127564 (P.N.), R01HL148050 (P.N.), R01HL151283
- 1056 (P.N.), R01HL148565 (P.N.), R01HL135242 (P.N.), R01HL151152 (P.N.); the American Heart
- 1057 Association 940166 (M.C.H.), 979465 (M.C.H.); the Korea Health Industry Development
- 1058 Institute HI19C1330 (S.M.J.C.); Harvard Catalyst Medical Research Investigator Training
- 1059 Program (A.P.P.); National Human Genome Research Institute U01HG011719 (A.P.P. and
- 1060 P.N.); the Belgian American Educational Foundation (A.S.); the U.S. National Institute of
- 1061 General Medical Sciences R35GM147197 (R.F.G.), R35GM124836 (R.D.); National Institute of
- 1062 Diabetes and Digestive and Kidney Diseases R01DK125782 (P.N.); National Institute of Child
- 1063 Health and Human Development R01HD101246 (D.M.H.); Preeclampsia Foundation (K.J.G.,

1064 R.S.); Fondation Leducq TNE-18CVD04 (P.N.); and the Massachusetts General Hospital Paul
1065 and Phyllis Fireman Endowed Chair in Vascular Medicine (P.N.).

1066

1067 The work was conducted under UK Biobank application 7089. The Trøndelag Health Study 1068 (HUNT) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health 1069 Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, 1070 Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. The 1071 aenotyping in HUNT was financed by the National Institutes of Health: University of Michigan: 1072 the Research Council of Norway; the Liaison Committee for Education, Research and 1073 Innovation in Central Norway: and the Joint Research Committee between St Olavs hospital 1074 and the Faculty of Medicine and Health Sciences, NTNU. The genetic investigations of the 1075 HUNT Study is a collaboration between researchers from the K.G. Jebsen Center for Genetic 1076 Epidemiology, NTNU and the University of Michigan Medical School and the University of 1077 Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed 1078 by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, 1079 Norway. DNA extraction and genotyping of nuMoM2b was supported by the Indiana University 1080 Precision Health Initiative. The authors thanks other members of the Estonian Biobank research 1081 team: Lili Milani, Andres Metspalu, Tõnu Esko, Mari Nelis, Reedik Mägi, and Georgi Hudjashov. 1082 Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the 1083 Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher Education 1084 Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for 1085 London substantive site), and research delivery support from the NHS National Institute for 1086 Health Research Clinical Research Network (North Thames). Genes & Health is/has recently 1087 been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry 1088 Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research 1089 and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk

1090 A/S, Pfizer Inc, Takeda Development Centre Americas Inc. The authors thank Social Action for 1091 Health, Centre of The Cell, members of our Community Advisory Group, and staff who have 1092 recruited and collected data from volunteers. We thank the NIHR National Biosample Centre 1093 (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King's College London), 1094 Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, sequencing 1095 and variant annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning Groups 1096 (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking 1097 and Dagenham). East London NHS Foundation Trust. Bradford Teaching Hospitals NHS 1098 Foundation Trust, Public Health England (especially David Wyllie), Discovery Data 1099 Service/Endeavour Health Charitable Trust (especially David Stables), NHS Digital for GDPR-1100 compliant data sharing backed by individual written informed consent. Most of all, we thank all 1101 of the volunteers participating in Genes & Health. Current Genes & Health Research Team (in 1102 alphabetical order by surname): Shaheen Akhtar, Mohammad Anwar, Elena Arciero, Omar 1103 Asgar, Samina Ashraf, Saeed Bibi, Gerome Breen, Raymond Chung, Charles J Curtis, Shabana 1104 Chaudhary, Maharun Chowdhury, Grainne Colligan, Panos Deloukas, Ceri Durham, Faiza 1105 Durrani, Fabiola Eto, Sarah Finer, Joseph Gafton, Ana Angel Garcia, Chris Griffiths, Joanne 1106 Harvey, Teng Heng, Sam Hodgson, Qin Qin Huang, Matt Hurles, Karen A Hunt, Shapna 1107 Hussain, Kamrul Islam, Vivek Iyer, Ben Jacobs, Ahsan Khan, Cath Lavery, Sang Hyuck Lee, 1108 Robin Lerner, Daniel MacArthur, Daniel Malawsky, Hilary Martin, Dan Mason, Rohini Mathur, 1109 Mohammed Bodrul Mazid, John McDermott, Shefa Miah, Caroline Morton, Bill Newman, 1110 Elizabeth Owor, Asma Qureshi, Samiha Rahman, Nishat Safa, Miriam Samuel, John Solly, 1111 Daniel Stow, Farah Tahmasebi, Richard C Trembath, Karen Tricker, Nasir Uddin, David A van 1112 Heel, Klaudia Walter, Caroline Winckley, John Wright, Julia Zollner. 1113

1114

1115 Ethics declarations

- 1116 M.C.H. reports consulting fees from CRISPR Therapeutics, advisory board service for Miga
- 1117 Health, and grant support from Genentech, all unrelated to this work. K.J.G. has served as a
- 1118 consultant for BillionToOne, Aetion, and Roche for projects unrelated to this work. R.S. is a co-
- 1119 founder of Magnet Biomedicine, unrelated to this work. R.D. reports receiving grants from
- 1120 AstraZeneca, grants and nonfinancial support from Goldfinch Bio, being a scientific co-founder,
- 1121 consultant, and equity holder for Pensieve Health (pending), and being a consultant for Variant
- Bio, all unrelated to this work. P.N. reports grant support from Amgen, Apple, AstraZeneca,
- 1123 Boston Scientific, and Novartis, spousal employment and equity at Vertex, consulting income
- 1124 from Apple, AstraZeneca, Novartis, Genentech / Roche, Blackstone Life Sciences, Foresite
- 1125 Labs, and TenSixteen Bio, and is a scientific advisor board member and shareholder of
- 1126 TenSixteen Bio and geneXwell, all unrelated to this work.

Table 1. Maternal sequence variants associated with p	preeclampsia/eclamps	sia.
-------------------------------------------------------	----------------------	------

				Discovery analysis (17,150 cases / 451,241 controls)						Follow-up analysis (2,914 cases / 251,876 controls)		Combined discovery and follow-up meta- analysis (20,064 cases / 703,117 controls)	
Nearest gene	Lead variant	CHR	POS	Effect allele / other allele	Weighted average EAF	OR	P-value	P(het)*	OR	P- value	OR	P- value	
Loci with gei	nome-wide signii	ficance ir	n discovery ana	lysis	1	1	1	1	1	İ.	i	-	
MTHFR / CLCN6	rs149764880	1	11820674	G/T	0.85	1.11	1.8e-8	0.30	1.17	6.8e-4	1.12	8.8e-11	
WNT3A	rs708119	1	228015567	C/G	0.67	1.08	2.3e-8	0.92	1.05	0.10	1.08	7.8e-9	
MECOM	rs9855086	3	169413542	A / T	0.53	1.08	5.7e-10	0.21	1.08	8.3e-3	1.08	1.6e-11	
FGF5	rs16998073	4	80263187	T/A	0.32	1.11	3.1e-14	0.15	1.08	1.6e-2	1.11	2.3e-15	
MICA	rs2442752	6	31383987	C / T	0.36	1.08	2.3e-9	0.57	0.99	0.84	1.07	3.8e-8	
LINC00484	rs5899121	9	91145498	TG / T	0.85	1.12	4.6e-8	0.31	0.86	0.31	1.12	1.4e-7	
PGR	rs2508372	11	101397592	A/G	0.79	1.10	1.3e-9	0.14	1.11	7.5e-3	1.11	3.4e-11	
SH2B3	rs10774624	12	111395984	G / A	0.47	1.10	2.9e-12	0.40	1.03	0.29	1.09	1.0e-11	
FLT1	rs7318880	13	28564148	T/C	0.48	1.09	6.7e-12	0.79	1.06	5.8e-2	1.09	1.6e-12	
FTO	rs1421085	16	53767042	C/T	0.40	1.10	4.7e-12	0.61	1.07	1.8e-2	1.09	3.3e-13	
RGL3	rs167479	19	11416089	G / T	0.55	1.10	7.6e-10	0.20	1.09	6.8e-3	1.10	1.8e-11	
ZNF831	rs259983	20	59160402	C / A	0.16	1.13	1.0e-12	0.40	1.15	2.8e-4	1.14	1.3e-15	
Additional lo	ci identified in co	ombined	discovery and f	ollow-up m	eta-analysis	1	1	1				_	
FGL1	rs2653414	8	17868560	A / C	0.02	1.27	1.0e-6	0.44	2.18	4.4e-9	1.36	3.4e-11	
UPB1	rs17572606	22	24472204	T/C	0.02	1.45	1.9e-7	0.33	1.28	6.0e-2	1.41	4.6e-8	

*P(het) indicates P-value for heterogeneity across discovery cohorts. CHR indicates chromosome. POS indicates position (genome build 38). EAF indicates effect allele frequency. OR indicates odds ratio.

Table 2. Maternal se	quence variants associated with	n gestational hypertension.
----------------------	---------------------------------	-----------------------------

					Discovery analysis (8,961 cases / 184,925 controls)				Follow-up analysis (2,066 cases / 227,863 controls)		discovery and follow-up meta- analysis (11,027 cases / 412,788 controls)	
Nearest gene	Lead variant	CHR	POS	Effect allele / other allele	Weighted average EAF	OR	P-value	P(het)*	OR	P- value	OR	P- value
Loci with gene	ome-wide signi	ficance ir	n discovery analys	sis			1		1			
MECOM	rs9855086	3	169413542	A / T	0.54	1.10	1.4e-9	0.51	1.04	0.28	1.08	6.6e-8
FGF5	rs16998073	4	80263187	T/A	0.32	1.12	4.6e-11	0.54	1.09	4.0e-2	1.12	1.5e-11
NPR3	rs13154066	5	32831564	C / T	0.58	1.11	6.1e-10	0.60	1.05	0.14	1.10	4.5e-10
TNS2 / CSAD	rs7139122	12	53173006	A / G	0.02	1.46	1.1e-9	0.13	1.05	0.65	1.37	8.3e-9
RGL3	rs167479	19	11416089	G / T	0.56	1.11	6.9e-9	0.76	1.12	4.6e-3	1.11	2.5e-10
PREX1	rs2208589	20	48791877	G / A	0.84	1.15	2.3e-8	0.17	1.11	2.8e-2	1.14	2.9e-9
ZNF831	rs260017	20	59141918	A / G	0.18	1.16	7.0e-13	0.32	1.14	5.4e-3	1.16	1.2e-13
Additional loc	i identified in co	ombined	discovery and foll	ow-up meta-an	alysis							
MTHFR / CLCN6	rs17367504	1	11802721	A / G	0.85	1.13	1.7e-7	0.63	1.19	4.6e-4	1.14	4.9e-10

*P(het) indicates P-value for heterogeneity across discovery cohorts. CHR indicates chromosome. POS indicates position (genome build 38). EAF indicates effect allele frequency. OR indicates odds ratio.

Table 3. Aspirin eligibility to prevent preeclampsia using major clinical risk factors and polygenic risk. This Table reports the proportion of participants in nuMoM2b (nulliparous women with singleton gestations recruited in the first trimester of pregnancy) who experienced each pregnancy outcome in the index pregnancy (normotensive pregnancy, gestational hypertension, or preeclampsia/eclampsia) who would have been identified as candidates for low-dose aspirin to prevent preeclampsia according to U.S. Preventive Services Task Force major criteria, with or without addition of preeclampsia/eclampsia and systolic blood pressure combination polygenic risk score (PRS_{preeclampsia+SBP}) as an additional criterion for aspirin eligibility. Net reclassification analyses reflect use of PRS_{preeclampsia+SBP} to up-classify risk for composite hypertensive disorders of pregnancy (HDPs) vs. normotensive pregnancy and for preeclampsia/eclampsia vs. other pregnancies when added to major risk factors.

						Preeclampsia vs. other pregnancy					
Total <i>N</i> =7,544	Normo- tensive pregnancy (<i>n</i> =5,744)	Gestational hypertension (<i>n</i> =1,319)	Preeclampsia/ eclampsia (<i>n</i> =481)	Net re- classification, HDPs vs. normotensive pregnancy (95% CI)	Net re- classification, preeclampsia vs. other pregnancy (95% Cl)	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	Negative predictive value (95% CI)		
Major risk factors only (<i>n</i> =656 [8.7%])	476 (8.3%)	96 (7.3%)	84 (17.5%)	Ref.	Ref.	17.5% (14.1-20.9%)	91.9% (91.3-92.5%)	12.8% (10.2- 15.4%)	94.2% (93.7-94.8%)		
Major risk factors or top 5% PRS (<i>n</i> =997 [13.2%])	699 (12.2%)	184 (13.9%)	114 (23.7%)	+2.7% (1.4 to 4.0%)	+1.8% (-0.3 to 4.0%)	23.7% (19.9-27.5%)	87.5% (86.7-88.3%)	11.4% (9.5- 13.4%)	94.4% (93.8-95.0%)		
Major risk factors or top 10% PRS (<i>n</i> =1,324 [17.6%])	928 (16.2%)	250 (19.0%)	146 (30.4%)	+4.1% (2.5 to 5.8%)	+4.3% (1.3 to 7.3%)	30.4% (26.2-34.5%)	83.3% (82.5-84.2%)	11.0% (9.3- 12.7%)	94.6% (94.1-95.2%)		
Major risk factors or top 25% PRS (<i>n</i> =2,298 [30.5%])	1,612 (28.1%)	460 (34.9%)	226 (47.0%)	+8.3% (6.0 to 10.7%)	+8.3% (3.9 to 12.6%)	47.0% (42.5-51.4%)	70.7% (69.6-71.7%)	9.8% (8.6- 11.1%)	95.1% (94.6-95.7%)		

Figure 1. Manhattan plots of preeclampsia/eclampsia and gestational hypertension in combined discovery and follow-up meta-analysis.

Manhattan plots (chromosomal position on the X-axis and -log(10) of the P-value on the Y-axis) are displayed for **(A)** preeclampsia/eclampsia in 20,064 cases and 703,117 controls and **(B)** gestational hypertension in 11,027 cases and 412,788 controls. Analyses included multi-ancestry meta-analysis of common variants (minor allele frequency \geq 1%). Loci are labeled by the gene nearest to the lead variant.



Figure 2. Polygenic prediction of preeclampsia/eclampsia and gestational hypertension in test cohorts. Polygenic risk scores (PRS) for preeclampsia/eclampsia and gestational hypertension were derived from our discovery genome-wide meta-analyses, tuned in the UK Biobank, and carried forward for testing in independent cohorts. Prevalence of preeclampsia/eclampsia vs. percentile of PRS_{preeclampsia+SBP} in **(A)** HUNT and **(B)** nuMoM2b. **(C)** Prevalence of gestational hypertension vs. percentile of PRS_{GH+SBP} in nuMoM2b. Distribution of PRS_{preeclampsia+SBP} by preeclampsia/eclampsia status in **(D)** HUNT and **(E)** nuMoM2b. **(F)** Distribution of PRS_{GH+SBP} by gestational hypertension status in nuMoM2b. Within each boxplot, horizontal lines reflect the median, top and bottom of the box reflect the interquartile range, and whiskers reflect the maximum and minimum value within each grouping.



Figure 3. Sex-stratified phenome-wide association study of preeclampsia/eclampsia and gestational hypertension polygenic risk in the UK Biobank. Preeclampsia/eclampsia polygenic risk **(A-B)** and gestational hypertension polygenic risk **(C-D)** were associated with 1,445 phenotypes among women (A, C) and men (B, D) in the UK Biobank. Associations with phenotypes were tested using logistic regression with adjustment for age and PC 1-5.



Extended Data

Extended Data Figure 1. Flow chart summarizing the study design and contributing cohorts.



Extended Data Figure 2. Results of multi-trait analysis of genome-wide summary statistics (MTAG) for preeclampsia/eclampsia from joint analysis of summary statistics for preeclampsia/eclampsia and gestational hypertension in discovery cohorts. The plot displays chromosomal position on the X-axis and -log(10) of the P-value on the Y-axis.



Extended Data Figure 3. Relative expression of prioritized genes in human aortic cells with single-nuclei RNA sequencing. We analyzed expression of genes prioritized by genome-wide meta-analysis of preeclampsia/eclampsia and gestational hypertension and secondary *in silico* analyses in a dataset of single-nuclei RNA sequencing from two normal human flash-frozen aortic specimens. Most prioritized genes were enriched in endothelial cell populations and/or macrophages.

